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Obesity prevalence is at an all-time high, with 1 in 3 Americans now classified as obese 
(1). Obesity is a debilitating condition that is associated with various co-morbidities, 
including type 2 diabetes (T2D), cardiovascular disease, pulmonary dysfunction, 
gastrointestinal disease, various cancers, and osteoarthritis. T2D is one of the most 
significant co-morbidities of obesity, as it often leads to other diseases such as non-
alcoholic fatty liver disease (NAFLD) and hyperlipidemia.   
There are now 347 million people worldwide with T2D (2).The incidence of newly 
diagnosed cases of T2D in America is at its highest of 1.9 million per year and, according 
to the American Diabetes Association, and if the trend continues, 1 in 3 Americans will 
have diabetes by the year 2050 (3). There are many factors that increase the risk of 
developing T2D, some which include being overweight and physically inactive, having a 
genetic predisposition, and high blood pressure. In addition, there are complications that 
develop gradually over a period of time during T2D if blood glucose sugar levels are not 
properly controlled. Long-term poor glucose control puts patients at a higher risk for 
complications such as cardiovascular disease (CVD), neuropathy, nephropathy, and 
retinopathy. 
Obesity and diabetes are having a substantial impact on the economic state of the health 
care system. The total estimated cost of diagnosed diabetes in 2012 was $245 billion. 
This includes $176 billion in direct medical costs and $69 billion in reduced productivity, 
encompassing lower labor force participation from chronic disability and premature 
mortality (4). In addition to the economic burden, there are substantial intangible costs, 
such as a reduced quality of life for those people with diabetes, and often for their 
families and friends as well.  
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Several epidemiological studies suggest that whole grain consumption is associated with 
a lower risk of obesity and T2D. Whole grain consumption has been found to have an 
inverse association with fat mass and insulin resistance in both humans and rats, possibly 
through several different mechanisms, involving mechanical, hormonal, and anti-
inflammatory processes. The mechanical mechanism focuses on alterations in caloric 
density and absorption of nutrients, the hormonal mechanism on changes in hormone 
synthesis and secretion due to nutrient availability, and lastly, anti-inflammatory and anti-
oxidative components in the whole grain. However, it is unclear which milling fraction of 
the whole grain, the bran, germ, or endosperm, may be responsible for these health 
benefits.   
Therefore, the aim of this study was to examine the effects of whole wheat and wheat 
milling fractions, specifically bran, germ, and endosperm, on glucose control, insulin 
resistance, fatty liver, and adiposity using an animal model of obesity with T2D, the 
Zucker Diabetic Fatty (ZDF) rat. Male ZDF rats were fed either a cornstarch-based diet 
(AIN-93G; obese control ), or diets containing 64% whole wheat flour, 54% refined 
wheat, 9.4 % wheat bran, 1.6% normal wheat germ, or high 15% wheat germ for 5 
weeks. Lean ZDF littermates fed a standard AIN-93G diet served as a negative control. 
All animals were fed ad libitum. The refined wheat, wheat bran, and wheat germ were 
present in the diets in the same concentration as would be found in the whole wheat diet. 
The high wheat germ diet had amounts of germ 10 times that of the normal wheat germ 
diet. It was found that after 5 weeks, the whole wheat, refined wheat, and high and 
normal wheat germ groups all showed a significant improvement (p<0.05) in area under 
the curve during glucose and insulin tolerance tests. There were no differences in body 
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weight or fat pad weight among the ZDF groups; however, there was a significant 
difference (p=0.031) in fat mass % between the whole wheat group and the obese control. 
The whole wheat group and all wheat fraction groups decreased the concentration of liver 
lipids compared to the obese control, and the bran and germ groups also had lower liver 
cholesterol concentration. Only the whole wheat group had a significantly lower cecum 
pH (p<0.0001) and greater cecal weight (p<0.0001) compared to the obese control, 
indicating greater fermentation of the diet. There were no significant differences in 
plasma adiponectin and resistin levels among the ZDF diet groups. In conclusion, the 
results of this study suggests that none of the wheat milling fractions stand out as 
responsible for the metabolic effects seen with consumption of whole wheat and that 
individual milling fractions of wheat are just as effective in improving insulin resistance 
and fatty liver as whole wheat. 
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 Chronic Disease, Obesity, and Type 2 Diabetes 
Obesity 
Obesity is defined as having an excessive amount of adipose tissue, indicated by a body 
mass index (BMI) of 30 or higher, and is associated with an increased risk for numerous 
diseases and health complications, such as cardiovascular disease (CVD), type 2 diabetes 
(T2D), high blood pressure, stroke, cancer, sleep apnea, depression, gallbladder disease, 
infertility, skin problems, and delayed wound healing issues, all of which are significant 
health problems and reduce quality of life (1). 
Obesity occurs when an individual consumes more energy than is expended through 
normal daily activities, exercise, and basal metabolic rate (BMR), causing the body to 
store the excess energy as fat. An individual’s genetic background can also be a risk 
factor for obesity, as it may influence how the body responds to nutrients which may 
cause weight gain in some instances (2). Genetic and hormonal influences  such as 
genetic mutations and hypothyroidism can affect body weight (3). There are also some 
more unusual causes that may be a result of underlying endocrine disorders. For example, 
Cushing’s syndrome, polycystic ovary syndrome, and Prader-Willi syndrome all lead to 
decreased physical activity and therefore, weight gain (4, 5).  
There are many approaches to treating obesity. Weight loss can generally be achieved 
with lifestyle changes such as increasing physical activity and altering eating behavior 
(6). Some of these diet modifications include following a low calorie diet, eating more 
fiber-rich foods such as whole grains, more plant based foods such as fruits and 
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vegetables, more lean sources of protein like beans, lentils, fish, lean beef, and meal 
replacements (7). Secondly, there are surgical methods that have been shown to be very 
effective at inducing weight loss such as gastric bypass and sleeve cut surgery. Lastly, 
pharmacological products such as Orlistat can assist in weight loss by inhibiting the 
absorption of fats from diet and therefore reducing the calories taken in by the body (8). 
Type 2 Diabetes 
T2D affects the body’s ability to control blood glucose levels. The primary defect in T2D 
is the reduced effectiveness of the hormone insulin. Insulin is released from pancreatic β-
cells into the bloodstream and targets the insulin receptor on muscle or adipose cells to 
cause the uptake of glucose (9). Several tissues show a reduced response to insulin and 
contribute to the development of T2D. The muscle and adipose tissue develop 
dysfunctional insulin signaling pathways, thereby preventing the uptake of glucose from 
the blood into the tissue cells (10). Additionally, the liver develops a selective insulin 
resistance that increases hepatic glucose output due to a failure in the glucose sensing 
mechanism (11). Without glucose uptake into the tissues, excessive glucose circulates in 
the blood stream and can glycosylate proteins, causing damage to the organs and nervous 
system (12). 
When we consume a meal during normal, non-diabetic conditions, blood glucose levels 
rise and the pancreas is able to sense this through the glucose receptor GLUT2. β-cells in 
the pancreas then release insulin into the circulation, signaling the muscle and adipose 
tissue to absorb glucose from the blood via the GLUT4 receptor (13). When an individual 
is constantly eating foods high in glucose and/or highly processed foods, where starches 
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are rapidly digested into glucose, there is continually high blood glucose and blood lipids 
(pre-diabetic state) which with time, develops into T2D (14).  
There are four stages to the progression of T2D. The first stage starts with normal insulin 
sensitivity but with high blood glucose levels, followed by the second stage, impaired 
glucose tolerance, which is due to a slight insulin resistance by insulin-sensitive tissues. 
As the cells become more insulin resistant, the third stage of hyperinsulinemia occurs, as 
the body tries to compensate for the insulin resistance by releasing more insulin into the 
blood. Eventually, in the last stage, there is an inadequate amount of insulin secreted 
(hypoinsulinemia) as the β-cells in the pancreas die due to lipid accumulation and 
oxidative stress (15). 
Normal fasting blood glucose levels are typically below 100 mg/dL, while in a pre-
diabetic state, blood glucose levels would range between 100 to 125 mg/dL. After an oral 
glucose tolerance test, if blood glucose remains lower than 140 mg/dL after 2 hours, then 
it is considered normal, but if it is between 140 to 199 mg/dL it is considered pre-
diabetic, meaning impaired glucose tolerance. Higher than 200 mg/dL is considered 
diabetic (16).  
There are various types of medications on the market to treat type 2 diabetes. These 
medications are divided into 4 groups as they work using different mechanisms. There 
are some that work by sensitizing the body to insulin (Biguanides and 
Thiazolidinediones), others that decrease hepatic glucose production (Dipeptidy 
peptidase-4 (DPP4) inhibitors) (17), some that stimulate the pancreas to make more 
insulin (Meglitinides and Sulfonylureas) (18) and lastly, others that slow absorption of 
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starches from the intestine (Alpha-glucosidase inhibitors), which then slows the rate of 
glucose entering the blood stream (19). 
Dietary and lifestyle changes are known to reduce the risk of T2D as well as maintain a 
healthy blood glucose level if already diagnosed with T2D. Some of these changes 
include exercise, consumption of monounsaturated and polyunsaturated fatty acids such 
as omega-3’s, which can decrease free fatty acids (FFA) in the blood stream, a known 
contributor to inflammation and insulin resistance (20), consumption of fiber and whole 
grains, and more extreme dietary methods such as caloric restriction and invasive 
surgeries like gastric bypass (21-23).  
Obesity related type 2 diabetes 
During obesity, a risk factor for T2D as mentioned previously, there is a state of low-
grade chronic inflammation which is thought to be a contributor to the progression of 
T2D. Excess white adipose tissue (WAT) can cause hypertrophy in the adipocytes 
leading to insulin resistance and increased adipogenesis (24, 25). This can result in an 
efflux of fatty acids from the adipocyte into the blood, which then circulate through the 
body and become deposited in the liver, muscle, and beta cells, causing disruptions in the 
insulin signaling pathway and therefore, cause insulin resistance (26-28). Increased 
amounts of WAT can also stimulate an immune response leading to release of pro-
inflammatory cytokines such as tumor necrosis factor α (TNF-α) and interleukin-6 (IL6) 
from the adipose tissue and from macrophages that have infiltrated into the adipose tissue 
from the blood, causing a low-grade inflammation (29). This inflammation also 
contributes to the insulin resistance already present in the liver and muscle, worsening 
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T2D. In addition to plasma FFA and macrophage-derived pro-inflammatory cytokines, 
the WAT also secretes the hormone leptin, which is involved with regulation of appetite 
and energy balance (30). During obesity leptin becomes ineffective as its receptors 
develop resistance due to the presence of saturated fats and ceramides that prevent its 
signaling from controlling appetite and body weight (31). Adipose tissue also secretes 
other adipokines, such as adiponectin and resistin, however when there is expanding 
WAT, the normal plasma concentration of these adipokines becomes altered (24). 
Adiponectin levels decrease with increased fat mass and insulin resistance (32). 
Adiponectin is known to improve insulin resistance by binding to the adiponectin 
receptors AdipoR1 and AdipoR2 and then activating adenosine monophosphate 
dependent kinase (AMPK) and PPAR-α (33). This activation then causes the cells in the 
liver and muscle to increase energy production pathways such as β-oxidation. Resistin on 
the other hand is correlated with increased body fat and is thought to increase insulin 
resistance (34, 35), but other studies have not found this (36). Lastly, during obesity, 
oxidative stress may increase as a result of an oversupply of FFA and glucose in the 
mitochondria which are then oxidized. As a result, there is greater reactive oxygen 
species (ROS) production which can activate protein kinase C (PKC) and c-Jun N-
terminal kinase (JNK), leading to interruption of the insulin signaling pathway (37). 
Insulin Resistance 
Insulin resistance during T2D is defined as the impairment of glucose uptake into insulin 
sensitive tissues such as muscle, liver, and adipose tissue. It can lead to hyperinsulinemia 
as the β-cells in the pancreas secrete greater quantities of insulin to control the excess 
glucose in the blood (15). The main defect in insulin resistance in the muscle is an 
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impaired signaling pathway, caused by the inhibition of serine phosphorylation on IRS-1, 
prohibiting downstream signaling and in the end, preventing glucose uptake through 
GLUT4 (38). The inhibition of serine IRS-1 phosphorylation can be caused by 
inflammatory pathways, activated by the cytokine TNF-α, and also by the accumulation 
of intracellular lipids such as free fatty acids, diacylglycerol (DAG), and ceramides (39). 
These lipids, which act as signaling agents, are increased during obesity and T2D and 
have been shown to activate the JNK and IκB kinase (IKK) stress response pathways to 
interrupt the insulin signal (40). Also, large amounts of ROS are produced through 
oxidation in the mitochondria due to the excess of fatty acids and glucose, which can 
cause mitochondrial dysfunction as well as mitochondrial death (41). Additionally, the 
liver becomes insulin resistant, and is no longer able to properly control glucose output 
while, at the same time, over-produces lipids from the excess glucose. Insulin resistance 
can also occur in the adipose tissue where it causes uncontrolled lipolysis, releasing more 
fatty acids into the circulation, further contributing to the accumulation of lipids in the 
liver and muscle (26-28). There are many mechanisms that cause insulin resistance but 
the focus here will be on three: inflammation, oxidative stress, and lipid accumulation in 
the liver.  
Inflammation 
A significant factor in the relationship between obesity and the development of insulin 
resistance is a chronic low-grade inflammation, particularly in the adipose tissue (42). 
During nutrient overload in adipose tissue, many stress pathways are triggered that 
stimulate the release of pro-inflammatory cytokines and adipokines into the circulation 
which contribute to the development of insulin resistance. Cytokines like TNF-α and IL-6 
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can act locally in the adipose tissue, initiating the recruitment of macrophages, which in 
turn secrete more cytokines and promote adipocyte cell death (43, 44). This creates a 
feed-forward loop that causes further inflammation. These pro-inflammatory cytokines 
circulate to other tissues, causing a constant, low-grade systemic inflammatory state (44, 
45).  
The low-grade chronic inflammatory state begins as a result of various effectors, some of 
which include endoplasmic reticulum (ER) stress, low adiponectin levels, higher leptin 
levels, uncontrolled lipolysis, macrophage infiltration, and adipocyte death (46). TNF-α 
is a pro-inflammatory cytokine produced mainly by macrophages and lymphocytes, 
however it can also be produced by adipose tissue in small amounts (47). TNF-α is 
thought to play an important role in insulin resistance through activation of stress kinases 
such as MAPK and JNK, which are able to phosphorylate serine residues on IRS-1, 
thereby stopping the insulin signaling pathway in the muscle (41). During obesity, the 
adipose tissue can over-express TNF-α and cause inflammation and a decrease in insulin 
sensitivity (46). TNF-α can also inhibit the nuclear receptor PPAR-γ, a transcriptional 
regulator of adipogenesis. As PPAR-γ controls the transcription of genes involved in the 
synthesis of triglycerides, reduced activity results in greater free fatty acid release from 
the adipocytes into the circulation, which then build up in the muscle and liver to cause 
insulin resistance (48). Inflammation mediators such as C-reactive protein (CRP) are also 
released through the action of TNF-α by the liver (64). 
IL‐6 is a multifunctional inflammatory cytokine produced mainly by adipose tissue and is 
involved in the progression of insulin resistance in the liver and muscle tissue (49). It 
belongs to the cytokine class I receptor family that are responsible for activating the 
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JAK/STATs inflammatory pathways. IL-6 levels in the blood are increased during 
obesity and can directly affect lipid metabolism in the liver by inducing VLDL secretion 
and causing hypertriglyceridemia (46) resulting in further inflammation and insulin 
resistance. It is unclear as to how this happens but it has been suggested to involve either 
tyrosine phosphatase activation, which is necessary for proper insulin signaling, or 
interactions between suppressors of cytokine signaling proteins and the insulin receptor. 
However, not all findings support a role for IL-6 in promoting insulin resistance, as it has 
been reported by Nieto-Vazquez et al. (50) that mice treated with IL-6 for 3 h stimulated 
glucose uptake in skeletal muscle, suggesting that acute exposure to IL-6 can actually 
improve insulin resistance.  
Altered secretion of adipokines 
The secretion patterns of adipokines are also altered during obesity and inflammation, 
such that adiponectin decreases and resistin increases, further contributing to insulin 
resistance. Resistin is produced in small amounts by the adipose tissue while the majority 
is secreted by macrophages and monocytes (46). The function of resistin is currently not 
completely understood but it is thought that it can induce insulin resistance in the muscle 
and liver (34). In-vitro studies using adipocytes have shown that resistin reduces insulin-
stimulated glucose transport as well as inhibits adipocyte differentiation, which suggests 
a link between obesity and insulin resistance within the adipose tissue (51). Obese mice, 
who are insulin resistant, have increased resistin levels (34). Further, it has been shown 
that infusion of resistin into lean animals induces insulin resistance (34). However, the 
relationship between resistin and insulin resistance remains uncertain, as it has been 
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reported that there is a decrease in the gene expression of resistin during insulin 
resistance (52).  
Adiponectin is another adipokine that is highly expressed in adipose tissue and released 
in large amounts into the circulation (53). Plasma adiponectin levels are inversely 
associated with obesity and insulin resistance, with lower concentrations present in obese 
and diabetic individuals and greater concentrations in insulin-sensitive individuals, and 
with increases during weight loss and (54, 55). Administration of adiponectin has been 
shown to reverse insulin resistance caused by adiponectin deficiency (32, 56). 
Adiponectin is believed to improve insulin resistance in the liver and muscle by 
activating AMP-activated protein kinase (AMPK), a kinase that acts as the master 
regulator for intracellular energy balance (57). Activated AMPK increases fatty acid β-
oxidation in order to remove harmful intracellular lipids and promote insulin sensitivity 
in the muscle as well as decreasing intracellular malonyl CoA in the liver, which leads to 
lower rates of lipogenesis (58, 59). Adiponectin is also known to regulate liver glucose 
production by decreasing expression of the key gluconeogenic enzymes 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) (60). 
In addition, it is also thought that adiponectin can reduce inflammatory responses caused 
by TNF-α and reduce the secretion of TNF-α from macrophages (61). 
Oxidative Stress 
Oxidative stress is a result of an imbalance between the production and disposal of ROS 
produced during energy metabolism. In the insulin resistant state, this imbalance is due to 
greater oxidation of fatty acids and glucose in the mitochondria (62-64) . Some ROS 
produced include free radicals, such as superoxide (·O2–), hydroxyl (·OH), peroxyl 
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(·RO), and hydroperoxyl (·HRO2–), as well as non-radical species such as hydrogen 
peroxide (H2O2) and hydrochlorous acid (HOCl) (65). These species can cause oxidation 
of proteins, lipids, and DNA and also inhibit enzymes in the electron transport chain, 
blocking mitochondria respiration and therefore diminishing normal cellular functions 
(41). All of these effects can cause cell injury and may lead to cell death. Increased ROS 
production and peroxidation of cellular components can lead to mitochondrial 
dysfunction and a reduction in mitochondria number (66). This dysfunction can then 
contribute to FFA and lipid accumulation, which may lead to the interruption of the 
insulin signaling pathway (67). Additionally, ROS themselves are known to inhibit the 
insulin signal by activating the PKC, JNK, and NF-B inflammatory pathways, as well as 
activating TNF-α and glucocorticoid signaling (64, 68). 
Lipid	Accumulation	in	the	Liver (Nonalcoholic Fatty liver) 
Non-alcoholic fatty liver disease (NAFLD) is a co-morbidity that accompanies T2D and 
obesity. This disease is classified as the accumulation of excess fat in the liver, 
accompanied by increased inflammation, which can eventually lead to more serious 
conditions such as liver scarring (69). Diagnosis of this disease requires evidence of 
hepatic steatosis, either by imaging or by histology, as well as another cause of secondary 
hepatic fat accumulation, hepatitis C infection, or medications (69). Diagnosis can be 
done by ultrasound imaging and measuring plasma levels of aminotransferase or, less 
commonly, by liver biopsy. World prevalence of NAFLD ranges from 6.3% to 33% in 
the general population whereas in obese and in T2D patients, the prevalence jumps to 
90% and 69% respectively (70). NAFLD is associated with many metabolic risk factors 
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liver (11). The liver has selective insulin resistance during T2D in which there is 
increased glucose output through gluconeogenesis while, at the same time, greater fatty 
acid production from lipogenesis. In the normal situation, as shown in Figure 1-1, when 
insulin is low, the transcription factor FoxO binds to the promoter region for 
gluconeogenic genes, increasing their transcription and ultimately, increasing glucose 
production and secretion into the plasma. When insulin is in high concentration, such as 
after a meal, insulin can suppress gluconeogenesis by causing the phosphorylation of 
FoxO, which can no longer bind the promoter region (72). However, in the insulin 
resistant state, insulin is unable to cause the phosphorylation of FoxO, and 
inappropriately high rates of gluconeogenesis occur (73). 
Additionally, the increase in insulin due to insulin resistance also activates the 
transcription factor SREBP-1c, which increases lipogenesis (11). These synthesized 
lipids either remain in the liver or are released into the blood within VLDL, as the liver 
cannot sense the high plasma glucose and attempts to send fat to other parts of the body 
to be used as energy (74). 
This buildup of hepatic triglyceride can lead to a continuous β-oxidation of fatty acids in 
the liver, which can interfere with the normal function of mitochondria. This creates 
oxidative stress, which, when accompanied by adipose-derived pro-inflammatory 
cytokines such as TNF-α, is believed to play an important role in the progression of liver 
damage in NAFLD (75). 
There are four stages to NAFLD (figure 1-2 (76)). The first stage is simple steatosis, 
second is non-alcoholic steatohepatitis (NASH), third is liver fibrosis, and the last stage is 
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Whole Grains  
There is growing evidence showing that whole grains play an important role in reducing 
the risk of chronic diseases like T2D and obesity, as well as reducing overall mortality 
rates, through improvements in glucose homeostasis (80, 81). Whole grains are composed 
of various vitamins, minerals, fiber, and bioactive phytochemical compounds which may 
have significant beneficial effects to health. Due to the large number of potentially 
beneficial components within whole grains, it is difficult to pin-point the actual 
component responsible, and therefore the mechanisms by which the whole grains may act 
to promote better health (80).  
It has been reported that whole grain consumption is associated with a lower mortality 
rate relative to refined flours (82). As a result, there have been numerous studies 
conducted to examine the differences between diets high in whole grains and diets high in 
refined grains. With wheat being one of the most consumed grains in the United States, 
whole grain wheat has been widely used in research and is seen as a viable food 
production path for making changes that increase the overall health of the population. 
Observational studies (83-86) (87) and animal studies (88, 89) have demonstrated that 
whole wheat consumption is beneficial for reducing risk of obesity and T2D, but there is 
minimal research on identifying which component of whole wheat is responsible for the 
positive biological effects. Many researchers suggest that the health benefits could be due 
to the synergistic action of many compounds in the wheat (90, 91). 
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Wheat and Wheat Fractions 
Wheat has become the predominate grain used in the United States food supply, as it has 
ideal properties for making consumer products such as breads, pastas, and baked goods. 
In addition, wheat is also consumed in side dishes and breakfast cereals as either wheat 
flakes or other forms like wheat berries (wheat kernels). There are two main varieties of 
wheat used in US food manufacturing, Triticum turgidum durum (durum wheat) and 
Triticum aestivum vulgare (bread wheat) (92). Bread wheat is described as soft or hard 
depending on what season the crop was harvested. Based on the color of the kernel, it is 
further classified as red or white (92). White wheat is most commonly used for making 
cookies, cakes, and pastries as it contains the least amount of gluten. It is also the most 
aesthetic in terms of color, has milder flavor characteristics, and less sweetener is needed 
to get the same level of sweetness than if red wheat was to be used. Red wheat has 
strong-flavored tannins compared to white wheat and has a higher percentage of gluten, 
and therefore, isn’t widely used for products other than bread, making it somewhat less 
commonly consumed by the population. Hard wheat has more protein and is a winter 
crop grown in southern climates while soft wheat is a spring crop that is harvested in the 
fall (91). The wheat kernel is divided into 3 fractions, the bran, the endosperm and the 
germ, which can be separated by milling. These fractions are then sold and used for 
various food products such as bread making. 
Whole wheat  
A kernel of wheat is composed of roughly 80-85% endosperm (starch, i.e., refined wheat 
or white flour), 12-18% wheat bran and 2-3% wheat germ, each of which have different 
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macronutrient and micronutrient compositions that serve various functions for 
germination and growth of the plant (90). Due to the inclusion of germ and bran, whole 
wheat is considered to be more nutrient dense when consumed compared to the refined 
wheat fraction.  
Bran 
Wheat bran is a multilayer substance composed of various fibrous components: outer 
pericarp, inner pericarp, testa, nucellar epidermis, and the aleurone layer. Both pericarps 
are made up of branched heteroxylans, inulin, cellulose, and lignins that contain many 
cross-links between polymer chains due to the high content of ferulic acid dimers (80). 
The nucellar epidermis contains arabinoxylans, which contain the phenolic acids and 
other antioxidants. The aleurone layer makes up 50% of the bran fraction and is mainly 
composed of cell walls, which contain β-glucans (soluble fiber), some protein, 
arabinoxylans, cellulose (insoluble fiber), and ferulic acid. It is also rich in nutrients such 
as phenols, phytates, minerals, and B vitamins like niacin and folate.  
Endosperm  
Wheat endosperm is primarily composed of starchy carbohydrate and comprises 80-85% 
of the wheat kernel (80). Refined flour is predominantly wheat endosperm and during the 
milling process, the endosperm is separated from the bran and the germ, most of the 
nutrients are removed except for the carbohydrates. The endosperm contains starch, small 
amounts of proteins, iron, and various B vitamins and vitamin E. In the United States, 
almost all of the refined wheat flour is enriched to replace certain nutrients that are lost 
when the bran and germ are removed in the milling process (93). 
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Germ 
The germ is 2.5-3.8% of the wheat kernel and is a potentially nutritious food supplement. 
It is a concentrated source of various healthy lipids, proteins, sugars, minerals, vitamins 
(especially tocopherols and B vitamins), phytosterols, policosanols, carotenoids, and 
flavonoids. The germ fraction contains relatively high amounts of unsaturated fatty acids 
and, because of this, can oxidize and become rancid quickly (94).  
Whole Grains and Chronic Disease 
Consumption of whole grain cereal products are associated with reduced obesity and 
lower insulin resistance, however the exact mechanism of action is unclear, as whole 
grains contain an enormous number of bioactive compounds that could be involved, such 
as phytochemicals, fiber, omega-3 fatty acids, trace elements, choline containing 
compounds, phytosterols, oligosaccharides, and B and E vitamins (90). Each of these 
compounds may have a beneficial impact on factors related to obesity and T2D, therefore 
it is difficult to pinpoint which individual components are responsible. As well as the 
individual compounds found in whole wheat, wheat is also separated into 3 different 
milling fractions, which can bring more uncertainty as to where the benefits are coming 
from. There have been few studies that compare the individual fractions of wheat using 
well-controlled designs, making it difficult to understand which milling fraction of whole 
wheat is most significant in lowering risk of chronic disease.  
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Epidemiological Studies 
There have been a number of epidemiological studies that have reported an inverse 
association between whole grain intake, including wheat, and chronic diseases such as 
obesity and T2D. In a meta-analysis, consumption of high amounts of whole grain 
products, such as whole-wheat bread, were associated with a 20-30 % reduction in the 
risk of T2D (87).  
In a prospective cohort study conducted in 2013, Parker et al. (83) found that whole grain 
consumption in postmenopausal women was associated with a decreased incidence of 
T2D. Women who consumed more than two servings per day of whole grains had a 43% 
reduction in the incidence of diabetes compared to women who did not eat any whole 
grains. Even those consuming only one serving per day showed a significant decrease in 
the hazard ratio for T2D incidence.  
Another recent cohort study conducted by Wirstrom et al. (84) also reported an inverse 
relationship between high whole grain intake and the risk of diabetes. In this study, they 
investigated whether a higher intake of whole grain (59.1 g/d compared with 30.6 g/d) 
protected against the development of T2D in men and women 35-56 years of age. They 
found that higher whole grain intake (> 59.1g/d as opposed to 30.6 g/d) was associated 
with a 34% lower risk of T2D.  
A prospective cohort study by Liu et al. (95) examined the associations of dietary fiber 
and whole or refined grain products with weight gain over 12 years, using food frequency 
questionnaires to collect dietary information. The results showed that, overall, women 
who consumed more whole grains weighed less (on average 1.5 kg) than women who 
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consumed fewer whole grains. The results suggest that with a dietary intake of 12 g of 
fiber there was less weight gain (8 lb) compared to those who had the smallest increase in 
intake, over the 12 year follow-up period. Weight gain was inversely associated with 
whole grain consumption but was also positively related to refined grain intake, 
suggesting that whole grains may be more beneficial for maintaining body weight than 
refined grains. In another study conducted by Steffen et al. (86), they observed that whole 
grain intake was associated with lower BMI and decreased insulin resistance in 
adolescents, especially among the heaviest persons.  
Thus, epidemiology studies suggest that individuals who consume high amounts of whole 
grains have better weight management and glucose control than those consuming lesser 
amounts of whole grains and/or greater amounts of refined grains. 
Animal studies 
There have been a number of animal feeding trials investigating the effects of whole 
wheat, refined wheat, and wheat bran on T2D and obesity (88, 89, 96), however, there are 
relatively few studies on the effect of wheat germ. 
In a study conducted by Adam et al. (88), the potency of different wheat milling 
fractions, whole wheat flour, white flour, and wheat bran, on lowering liver lipids and 
cholesterol as well as their effect on colonic fermentation, was evaluated in rats. The diet 
groups in this study consisted of each milling fraction. The whole wheat diet was 
composed of 70% whole wheat flour, the refined white flour diet was 48.6% refined flour 
and the wheat bran diet consisted of 21.4% wheat bran. The whole wheat-fed and bran-
fed rats showed decreased hepatic cholesterol compared to the control group (fiber free) 
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and all wheat diets showed reduced liver triglycerides compared to the purified fiber-free 
control group. There were no differences in body weight after consuming the wheat diets 
for 3 weeks. Rats fed whole wheat flour and white flour showed a significant increase in 
cecum weight (+70% and +59%, respectively, P < 0.001) compared to control group, 
whereas rats fed the bran diet only showed a slight increase in cecum weight, suggesting 
greater fermentation in the 3 treatment diets. This study suggests that whole wheat flour, 
bran, and endosperm are all capable of reducing liver cholesterol and lipids, but have no 
effect on weight gain. 
Another study conducted by Choct et al. (89) examined the effects of whole wheat and 
white (refined) flour from two wheat varieties that differed in fiber content on plasma 
cholesterol in rats. They also determined the concentration of soluble and insoluble fiber 
of the flours, which was different between the two wheat varieties, as this difference may 
result in altered digesta viscosity which may have an impact on cholesterol absorption. 
The flours were processed to a particle size of 2 mm and the diets were composed of 75% 
milled whole wheat and white (refined) flour and fed for 18 days. The results show that 
plasma cholesterol concentrations were lower in rats fed white wheat compared to whole 
wheat, regardless of wheat type, however there was no change in body weight. The 
amount of bile acids and cholesterol in the cecum was greater in rats fed the white wheat 
flours compared to the whole wheat flours but were unaffected by wheat variety. This 
study indicates that white wheat flour, in comparison to whole flour, may increase the 
excretion of cholesterol and bile acids in the feces, and that this may be the reason for the 
lower plasma cholesterol in these groups. The data from previously described animal 
studies are inconsistent, Adam et al. suggests that whole wheat, wheat bran and refined 
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wheat can lower liver cholesterol. However Choct et al. suggests that refined wheat 
lowers plasma cholesterol more than whole wheat and therefore reduces the risk of 
cardiovascular disease. These studies did not find an effect on body weight gain by 
refinement state of flour, and thus do not support the epidemiological associations of 
lower body weight with greater consumption of whole wheat.  
Previously in our laboratory, we have shown that whole wheat consumption has a modest 
effect on the development of type 2 diabetes in the Goto–Kakisaki rat (97). Rats that were 
fed 65% whole wheat flour compared to a standard rat diet, the AIN-93G diet, had 
reduced fasting blood glucose after 2 months but not after 5 months. Whole wheat did not 
improve other measure of glucose control, including insulin secretion, glycated 
hemoglobin, oxidative stress, and β-cell mass. This study also examined the effects of 
other whole grains like oats, barley and maize, which also showed no effect on glucose 
control compared to the control diet. In this polygenetic model of diabetes without 
obesity, whole wheat consumption did not provide long term protection against the 
development of T2D. 
Clinical studies 
Clinical trials have shown that regular intake of whole grain cereals can contribute to 
lower risk factors related to non-communicable chronic diseases such as diabetes and 
obesity. In a short-term, randomized cross-over design study conducted by Kim et al. 
(98), obese women consumed a meal containing fiber from only wheat (primarily 
insoluble fiber), from only barley (soluble fiber) or a combination of the two grains. After 
a two day control diet, the women were given the test meal and their blood glucose and 
23 
 
insulin responses were measured for 3 h. There was no significant difference in the 
plasma glucose AUC, however the insulin response was significantly lower in the barley 
group compared to the meal containing only whole wheat. As a lower glucose and insulin 
response are beneficial for controlling blood glucose, this study suggests that whole 
wheat may not be helpful for reducing the risk of T2D compared to diets that have more 
soluble fiber. Clinical trials that fed whole grains for longer periods of time and measured 
variables more informative of insulin resistance, such as HOMA (an index of insulin 
resistance), or glycated hemoglobin, a measure of long-term blood glucose control, show 
no benefit compared to refined grains (99-101). In a crossover design study by Kristensen 
et al. (99), refined wheat was replaced by whole wheat in the diets of 79 overweight or 
obese women for 12 weeks. No differences were found in measures of blood glucose 
control, including fasting plasma glucose, plasma insulin, HOMA, or glycated 
hemoglobin. They also observed no changes in bodyweight or BMI, but did note a slight 
reduction in fat mass. In a randomized control trial, subjects were fed diets high in either 
refined wheat or whole wheat for 12 weeks (100). At the end of the study, there were no 
differences in fasting plasma glucose or insulin, HOMA, or another index of insulin 
resistance called QUICKI, between the refined wheat group and whole wheat group. In a 
smaller crossover design study, Giacco et al. (101) fed 15 subjects whole wheat foods or 
refined wheat foods for a period of 3 weeks. Here again, as in previous studies, fasting 
plasma glucose, insulin, and HOMA were not different between the groups. Plasma free 
fatty acids and bodyweight were also similar. Two other clinical trials using whole grain 
treatments also show no difference in bodyweight or BMI (102, 103). There have been 
few clinical trials that examine the effect of individual wheat milling fractions. Jenkins et 
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al. (104) examined the effect of wheat bran on glycemic control in a randomized 
crossover trial. After 3 months of consumption of 19 g/d wheat bran, there were no 
significant differences between the control and wheat bran groups in body weight, fasting 
blood glucose, or glycated hemoglobin. There is also little evidence that wheat germ is 
beneficial. In a 4 week study by Cara et al. (105), healthy adults were fed diets 
supplemented with 30 g of wheat germ per day. No changes in body weight or fasting 
plasma glucose were found, however they did observe a significant reduction in plasma 
triglycerides. Thus, the results of clinical trials do not appear to support the 
epidemiological observations suggesting that whole wheat consumption improves insulin 
resistance or reduces obesity.  
Possible	mechanisms of action of wheat on diabetes and obesity  
While clinical studies show no effect of whole wheat on glucose control, epidemiological 
and some animal studies suggest otherwise, therefore possible mechanisms need to be 
investigated. Studies have been conducted to investigate mechanisms potentially 
responsible for the health benefits of whole wheat, particularly for the diabetic and obese 
populations. It is thought that the mechanism responsible is through decreasing blood 
glucose levels, liver lipids, and a decrease in body weight (106).  
Several mechanisms by which blood glucose levels and cholesterol are reduced by whole 
wheat have been proposed, including properties of dietary fiber such as colonic 
fermentation and viscosity, a decreased rate of starch digestion due to slower gastric 
emptying, particle size effects, or the actions of phytochemicals. Colonic fermentation of 
dietary fiber by the gut microbiota leads to the production of short chain fatty acids 
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(SCFA) which may also have an impact on the body’s metabolism by increasing transit 
time through the digestive tract and perhaps the rate of absorption of glucose. Increased 
viscosity of intestinal contents by dietary fibers slows the absorption of glucose, thus 
reducing the glycemic index of a meal (107). Reduced gastric emptying and an increased 
particle size of the diet slow the digestion rate of starch which can reduce the 
postprandial glucose curve. Lastly, phytochemicals such as ferulic acid, which is the 
predominant phenolic acid in wheat, may have anti-inflammatory and anti-oxidative 
properties which help decrease inflammation and oxidative stress and in turn, insulin 
resistance.  
Dietary Fiber  
Dietary fiber has consistently been shown to have health benefits such as decreased 
cholesterol. Wheat fiber is mainly composed of insoluble fiber that is minimally 
fermented, but it also has a small amount of soluble fiber in the form of arabinoxylans 
(108). The insoluble part primarily assists with bowel movements by increasing stool 
mass (109). Soluble fiber has several well accepted health benefits, such as lowering 
plasma cholesterol and improving blood glucose in type 2 diabetes patients, and may 
assist with weight maintenance and decreasing low-grade inflammation by decreasing 
plasma C-reactive protein levels (101). A high consumption of dietary fiber has also been 
associated with a lower risk of developing coronary artery disease, hypertension, obesity, 
T2D, and colon cancer (110).  
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To understand how dietary fiber may reduce plasma cholesterol it is necessary to 
understand cholesterol metabolism. Cholesterol is obtained either from endogenous 
production in the liver or from exogenous sources, that is dietary cholesterol. Cholesterol 
homeostasis is maintained by the liver and can be used for the synthesis of steroid 
hormones and integration into cell membranes (111). Excess cholesterol is stored as 
cholesteryl esters in the liver. The main route for cholesterol catabolism is through the 
synthesis of bile acids (111). Cholesterol in the body can be lowered through excretion of 
cholesterol itself or by bile acids in the feces. As bile acids are synthesized from 
cholesterol in the liver, greater excretion forces the liver to continuously synthesize new 
bile acids from stored cholesterol, thereby lowering circulating cholesterol (111).  
Soluble fibers such as β-glucans have been shown to lower plasma LDL cholesterol. 
There are several possible mechanisms for this effect (112). One is through its effect on 
postprandial glycemia due to the viscosity of soluble fibers, which reduces the rate of 
intestinal absorption of glucose and in turn, decreases the level of insulin in the blood 
(113). Reduced insulin levels may lead to decreased cholesterol synthesis, as insulin may 
increase the gene expression of HMG-CoA reductase, the rate-limiting cholesterol 
synthesizing enzyme, through SREBP-1c (114). However, this mechanism seems 
unlikely, since viscous fibers have been shown to increase hepatic cholesterol synthesis 
in rats (115). Another possibility is that increased viscosity in the small intestine can 
hinder the emulsion and interfere with the formation of small micelles, limiting the ability 
of the digestive tract to absorb all the cholesterol present (116).  
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Particle size, starch structure, and the glycemic index 
Starch structure in wheat can have a profound effect on the postprandial glucose and 
insulin responses by slowing the absorption of glucose (117). Diets that yield a reduced 
glucose and insulin response are believed to lower the risk of obesity and T2D (118). In a 
study conducted by Jarvi et al. (119), the effect of glycemic index in a diabetic population 
was examined by altering food structure but maintaining identical nutrient composition. 
The patients were given two meals that differed in the structure of the starch sources. One 
meal consisted of whole red kidney beans, parboiled rice and bread made from whole 
wheat grains while the other meal was sticky rice, ground kidney beans and bread made 
from ground wheat grains. The results showed that the AUC for blood glucose and 
plasma insulin where significantly lower (P< 0.001) in patients who consumed the meal 
that had a preserved structure and bigger food particle size. Similarly, Holt et al. (120) 
found that subjects fed coarse flour and cracked grain, which have a larger particle size 
and a less-disrupted starch structure, had decreased glucose and insulin responses 
compared to those fed fine flour. Contrarily, meals that contained white or finely ground 
whole wheat flours resulted in similar glucose responses. However, the standard whole 
wheat flour particle size may have been milled too finely for a difference to be 
discernable (121). 
Further study of the influence of particle size was conducted by Vincent et al. (122), who 
examined the effect of fine and coarse bran (15 g/day) on gastric emptying and small 
bowel transit in a three way crossover study. This study included males and females of 
age 19-23 who were given a meal of either 15 g of fine or course bran, along with labeled 
rice, with gastrointestinal transit time measured using scintigraphic imaging. The results 
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showed that the time to reach 50% gastric emptying was significantly delayed by the 
course bran compared to the fine bran. However, there was no difference in small bowel 
transit time. The mechanism of action suggested was a reduced pyloric flow with the 
coarse bran meal due to an increased viscosity of the gastric contents. Another 
mechanism may be a selective retention of large particles (>2 mm) by the pylorus in the 
stomach, including particles containing starch, thus slowing movement of starch into the 
small intestine. Surprisingly, the addition of coarse bran or small plastic particles to the 
meal can actually speed up transit time in the small bowel, once the material has passed 
through the stomach (123). This may explain the laxation effect of bran. 
The ratio of amylose to amylopectin in wheat starch can also have significant effects on 
the glucose and insulin responses to a meal (124). High amylose products produce a 
lower blood glucose and insulin response when compared with similar products high in 
amylopectin, due to reduced branching and the lower solubility of amylose (117). In-vitro 
digestion of chewed barley samples, differing in amylose content, showed that samples 
with a low amylose content were hydrolyzed more quickly than grains with a high 
amylose content (125). In a study conducted by Kabir et al. (124) the consumption of 
mung bean containing 35% amylose and cornstarch containing 0.5% amylose was 
evaluated in rats. They found that the high amylose mung bean diet group produced a 
lower glucose response compared to the low amylose cornstarch group. In another study 
in which rats were fed either a high amylose/low amylopectin starch or a low 
amylose/high amylopectin starch, the low amylose/high amylopectin group had a greater 
glucose and insulin response as well as a greater bodyweight and higher insulin resistance 
compared to the high amylose/low amylopectin (126). Therefore the presence of high 
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amylose rather than amylopectin appears to reduce the response of glucose and insulin to 
a meal. 
Colonic fermentation 
Certain types of indigestible carbohydrates consumed in a meal can be fermented in the 
colon by various bacteria (127). This fermentation results in the production of microbial 
metabolites including the SCFAs, acetate, propionate, and butyrate, as well as carbon 
dioxide and hydrogen gases, and vitamins K and B12 (127). These microbiota-produced 
metabolites can interact with receptors on epithelial cells and sub-epithelial cells causing 
the release of hormones that affect food intake and energy metabolism of the host (127). 
There have now been several studies demonstrating that whole grains are able to change 
the gut microbiota composition in the colon, increasing species that produce SCFAs 
(128). It has been demonstrated that the presence of SCFA in the colon can promote the 
secretion of PYY and GLP-1,  which are able to slow the rate of gastric emptying and 
small bowel movement (129). However, recent evidence suggests that only fermentation 
of fructans such as inulin, is able to increase the concentration of PYY in the blood 
compared to other fermentable fibers like β-glucans (130). Soluble fibers such as guar 
gum, inulin, and pectin are highly fermentable while insoluble fibers like cellulose and 
wheat bran are minimally fermented (131).  
Cani et al. (132) has shown that supplementation of the fructans oligofructose, a short 
chain fermentable fiber, in the diet of high fat-fed diabetic mice for 4 weeks, improved 
their glucose tolerance, fasting blood glucose, and glucose-stimulated insulin secretion, in 
addition to reduced body weight gain. However, in a long-term study conducted by Isken 
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et al. (133), mice fed the soluble fiber guar gum for 45 weeks showed a significant 
increase in body weight as well as increased plasma glucose AUC during an insulin 
tolerance test compared to mice fed insoluble fiber. It was suggested that soluble fiber 
increased energy extraction from the diet, causing weight gain. Lastly, in a human study 
by Luo et al. (134), type 2 diabetic subjects who consumed 20 g/d of short-chain 
fructooligosaccharides for 4 weeks had no improvement in their fasting plasma glucose, 
plasma glucose AUC during an insulin tolerance test, or glycated hemoglobin compared 
to a control group who were fed sucrose. At this time the data suggest that fermentation 
of soluble dietary fibers may not be able to reduce the risk of T2D. 
Ferulic acid in the prevention of diabetes 
Ferulic acid (FA) is a phenolic acid found in the seeds and leaves of most plants, and is 
the predominant phenolic acid found in wheat bran (135). FA is an antioxidant that 
neutralizes free radicals such as superoxide, nitric oxide, and hydroxyl radicals that may 
cause oxidative damage to cell membranes and DNA (136, 137). Whole grains such as 
wheat and oats have a high concentration of ferulic acid. However, the ferulic acid is 
mostly bound to the cell wall in the grains and therefore is only slightly bioavailable due 
to limited release by gut microbiota (138). However, ferulic acid can be freed from cell 
wall components through processing methods such as fermentation and alkaline 
treatment. Ferulic acid supplementation at relatively low doses has been shown to 
increase the activities of antioxidant enzymes, thus neutralizing free radicals which, in 
diabetes, are a primary cause of accelerated tissue damage (139). While ferulic acid is a 
strong antioxidant, it is unlikely that the amount absorbed from wheat, where it is bound 
and unavailable, has a meaningful effect on overall antioxidant status through classical 
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mechanisms as a free radical scavenger (139). However, supplementation of ferulic acid 
has beneficial effects on various chronic diseases, especially type 2 diabetes (135, 140). 
In streptozotocin-induced diabetic rats, supplementation of purified ferulic acid (10 
mg/kg/d) for 6 weeks resulted in lower fasting blood glucose, TBARS, and free fatty 
acids and greater pancreatic islet mass (141). In another study using OLETF rats, a less 
severe model of insulin resistance than streptozotocin-induced diabetes, ferulic acid (10 
mg/kg/d) supplemented for 20 weeks resulted in a decrease in the plasma glucose AUC 
during glucose and insulin tolerance tests and greater plasma adiponectin, compared to 
rats not supplemented with ferulic acid (135). In high fat-fed mice, ferulic acid 
supplementation for 7 weeks decreased body weight and plasma and liver triglycerides 
(140). These studies suggest that supplementation of ferulic acid may be a viable 
therapeutic method for reducing the progression of obesity and T2D. 
Phytosterols as a mechanism in decreasing cholesterol 
Studies have shown that plant sterols are able to decrease intestinal cholesterol absorption 
and therefore reduce LDL cholesterol in the plasma (142, 143). Plant sterols are similar in 
structure to cholesterol and therefore use the same mechanism for solubilization in the 
lumen and for absorption from the intestine lumen into the enterocytes. Plant sterols are 
more hydrophobic compared to the cholesterol and therefore have a higher affinity for 
incorporation into the micelles. This causes the cholesterol to remain in the lumen instead 
of the micelles, therefore reducing intestinal absorption  and increasing cholesterol 
excretion in the feces (144). The presence of plant sterols in the wheat germ could 
therefore have an impact in lowering LDL cholesterol. 
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Study	Aim	
Evidence from epidemiological and animal studies suggests that whole grain intake is 
beneficial in decreasing obesity and insulin resistance, whereas clinical studies do not 
show the same result. Further work is necessary in this area to more fully understand the 
underlying health benefits of whole grains, particularly whole wheat. Currently there are 
no studies that investigate the effect of individual wheat milling fractions, compared to 
whole wheat, on T2D and obesity. Therefore, the aim of the following study was to 
examine the effects of whole wheat and wheat milling fractions on glucose control, 
insulin resistance, and fatty liver using an animal model of obesity with type 2 diabetes.  
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Chapter 2: Whole Wheat and Wheat Milling Fractions 
Improve Glucose Control and Reduce Non-Alcoholic Fatty 
Liver in the Zucker Diabetic Fatty Rat 
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Purpose: Whole wheat has been shown to improve glucose control and insulin resistance, 
and decrease fatty liver. However, which milling fraction is responsible for these positive 
effects is unknown. Therefore, this study examined the effects of whole wheat flour and 
its milling fractions, bran, germ and endosperm (refined wheat), on glucose control, 
insulin resistance, fatty liver, and adiposity, in an animal model of obesity with type 2 
diabetes, the Zucker Diabetic Fatty (ZDF) rat. 
Methods: Male ZDF rats were fed ad libitum either 64% whole wheat flour, 54% refined 
wheat, 9.4 % wheat bran, 1.6% wheat germ or 15% wheat germ (hi-germ) for five weeks. 
ZDF obese control and lean ZDF littermates (negative control) groups were fed a purified 
diet containing 50% cornstarch. The refined wheat, wheat bran and wheat germ diets 
were present in the same concentration as would be found in the whole wheat diet.   
Results: After 5 weeks, the whole wheat, refined wheat, wheat germ, and high-germ 
groups showed significant reductions in plasma glucose AUC during glucose and insulin 
tolerance tests compared to the obese control (p<0.05). There were no differences in body 
weight or fat pad weight among the ZDF groups but there was a significant reduction in 
fat mass % in whole wheat group compared to the obese control group (p=0.031). The 
whole wheat group and all wheat fraction groups decreased the concentration of liver 
lipids compared to the obese control and the bran and both germ groups had lower liver 
cholesterol (p<0.05). Only the whole wheat group had both a greater cecum pH 
(p<0.0001) and cecal weight (p<0.0001) compared to the obese control, indicating 
greater fermentation of whole wheat diet. There were no significant differences in plasma 
resistin concentrations among the ZDF diet groups. However, plasma adiponectin 
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concentrations were significantly lower in the whole wheat group compared to the obese 
control group (p= 0.032). 
Conclusion: The results show that each individual milling fraction is as beneficial as 
whole wheat itself in slowing development of insulin resistance and reducing fatty liver, 
and that the effects of the milling fractions are not additive.  
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Introduction 
Chronic non-transmittable diseases (NCD) such as obesity and type 2 diabetes (T2D) 
previously occurred predominantly in developed nations but are now becoming more 
common in developing countries, outnumbering transmissible diseases (3). There are now 
347 million people worldwide with T2D. In the United States alone there are 18.8 million 
people with T2D and another 79 million people in a pre-diabetic state (3). The incidence 
of newly diagnosed cases of diabetes is at its highest with 1.9 million per year. It is 
predicted that 1 in 3 Americans will have diabetes by the year 2050 if these trends 
continue (145). Often accompanying T2D, obesity is also at an all-time high with 1 in 3 
Americans being obese (1). Due to the magnitude of the prevalence of obesity and T2D, 
they are now in the top ten causes of death in North America, and therefore are among 
the greatest public health concerns. (1). 
Changes in lifestyle, food habits, and decreased physical activity are implicated in the 
rapid increase in obesity and T2D. The combination of diabetes and obesity is 
particularly harmful as it increases the risk of comorbidities, such as heart disease, kidney 
disease, nerve damage, dyslipidemia, blindness, and nonalcoholic fatty liver disease 
(NAFLD), drastically increasing mortality rates. Occurring in 70% of type 2 diabetes 
patients, NAFLD results from increased fat accumulation in liver cells (146). This can 
cause inflammation and increase the rate of gluconeogenesis which will aggravate 
hyperglycemia and increase the risk of T2D (147).  
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Several epidemiological studies suggesting that whole grain consumption can decrease 
the risk of obesity and T2D. A recent observational cohort study found that people who 
ingested whole grain cereals had 30% less risk of developing type 2 diabetes (84). Whole 
grain consumption has been found to be inversely associated with body fat mass and 
insulin resistance in both humans and rats (83). However, it is unclear which milling 
fraction of the whole grain, the bran, germ, or endosperm, is responsible for these health 
benefits.  The bran contains high concentrations of dietary fiber, which is thought to 
reduce obesity and diabetes by slowing down the digestion and absorption of digestible 
carbohydrates as well as increasing feelings of fullness (148). It also contains large 
quantities of ferulic acid which has been suggested to have anti-inflammatory and 
hepatoprotective properties and to improve glucose control (135, 140). The germ is high 
in vitamins, minerals and essential fatty acids which may reduce inflammation and 
improve immune system function (149). Currently there are no studies that investigate 
the effect of individual wheat milling fractions, compared to whole wheat, on T2D and 
obesity. Therefore, the aim of this study was to examine the effects of whole wheat and 
wheat milling fractions on glucose control, insulin resistance, and fatty liver using an 
animal model of obesity with type 2 diabetes.  
Methods and Materials 
Animal Model 
Choosing the correct animal model for the research objective is very important, as it will 
dictate the reliability of the results. The Zucker Diabetic Fatty (ZDF) rat was chosen in 
this experiment because it is a good model for studying the initial stages of type 2 
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diabetes with obesity. This rat model has a nonsense mutation in the leptin receptor gene, 
which is normally expressed most abundantly in the brain (150). This results in a  
defective leptin receptor, resulting in an absence of leptin signaling in the brain and 
causing hyperphagia. Characteristics of this model include obesity, insulin resistance, 
hyperinsulinemia, type 2 diabetes, hyperlipidemia, fasting hyperglycemia and 
hypercholesterolemia (151). At 5 weeks of age their initial weight ranges from 80 to 140 
g and at week 10, from 280-380 g (152). The ZDF rats have lean ZDF counterparts which 
are much smaller and do not develop obesity or T2D. Since our research objective was to 
assess metabolic changes associated with the onset of obesity and T2D during a whole 
wheat and wheat milling fraction dietary intervention, the ZDF rat appeared to be an 
appropriate model.  
 
Housing and care 
The ZDF rats were purchased from Charles River Laboratories (Wilmington, MA) at 5 
weeks of age. They were housed individually with a 12h light and dark cycle with food 
and water provided ad libitum. The animals were handled according to the National 
Institutes of Health guidelines and experimental procedures were approved by the 
University of Minnesota Animal Care and Use Committee. 
Diet 
There were 7 diet groups of 10 animals each. The positive control (ZDF) and the negative 
control (ZDF lean) were fed the AIN-93G purified diet (153). The remaining 5 ZDF 
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groups were fed diets containing either 64% whole wheat flour, 54% refined wheat, 9.4 
% wheat bran, 1.6% wheat germ, or 15% wheat germ for 5 weeks (Table 1). 
Soft white wheat and its milling fractions were sourced from a milling company (Star Of 
the West Milling Co., Frankenmuth, MI) and stored at 4º C. A proximate analysis was 
conducted to determine the protein, carbohydrate, lipid, total dietary fiber, and ash 
content of the whole wheat and milling fractions (Medallion Laboratories, MN, USA). 
The results of the analysis were used to formulate the diets, ensuring that they were 
matched for macronutrient content and therefore were isoenergetic. A final analysis of 
the diets was conducted to check for the concentration of resistant starch and fibers. The 
diets were formulated so that the amount of the milling fraction present in the bran, 
refined, normal wheat germ diets were the same as they would be present in the whole 
wheat diet. The high wheat germ diet had 10 times the amount of germ present in the 
normal germ diet. 
Experimental design 
The animals were fed the diets ad libitum for 5 weeks. A meal tolerance test was 
conducted at the end of week 1, an insulin tolerance test and a glucose tolerance test at 
the end of week 3, a urine collection at the end of week 4, and a 48 h fecal collection was 
done at the beginning of week 5. In addition, body composition was determined by dual 
x-ray absorptiometry (DXA) scanning (Lunar Prodigy Advance, GE Healthcare, 
Piscataway, NJ) at the end of week 4. At the end of week 5, 12 h fasted rats were 
anesthetized by isoflurane, blood collected by cardiac puncture into tubes containing 
EDTA (1 mg/mL), and the kidneys, liver, epididymal, inguinal, and retroperitoneal fat 
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pads were harvested and stored at -80° C. The blood was centrifuged, plasma collected, 
and then stored at -80° C until analysis. The pH of the cecal contents was measured using 
a combination spear-tip pH electrode (model 81-63, Orion Research, Boston, MA) and 
then the cecum was emptied of contents, flushed with distilled water and weighed. Feces 
were freeze-dried, weighed and stored at -50 °C. At 4 weeks, rats were placed in 
metabolic cages with free access to food and urine collected over 24 h which was then 
frozen at -50 °C until analysis. Body weight was measured weekly and food intake was 
measured at weeks 1, 2, and 3.  
Plasma analysis 
Plasma glucose was measured in whole blood using a glucometer (AlphaTrak, Abbott 
Laboratories, Abbott Park, IL) calibrated for rodents. Fasting plasma adiponectin was 
measured using an ELISA kit (Millipore, Billerica, MA) and fasting plasma resistin was 
measured using an EIA kit (Cayman Chemicals, Ann Arbor, MI). Fed-state plasma 
insulin was measured using a rat-specific radioimmunoassay kit (Millipore). 
Meal, glucose, and insulin tolerance tests 
During the meal tolerance test, 12 h fasted rats were fed 2.5 g (1.33 g digestible 
carbohydrate) of their respective diets and allowed 20 minutes to consume the meal. 
Blood glucose was measured at time intervals of 0, 15, 30, 60, 90, and 120 minutes after 
presentation of the meal and ~250 L blood collected at time points 0, 30, 60, 90, 120, 
and 180 minutes to measure plasma insulin. 
41 
 
During the glucose tolerance test, 12 h fasted rats were given glucose via gavage (0.5 
g\kg) and blood glucose was measured using a glucometer at time points 0, 15, 30, 60, 
90, 120, and 180 minutes. Area under the curve (AUC) was calculated by the trapezoidal 
rule, using a blood glucose concentration of zero as a baseline. 
 During the insulin tolerance test, insulin (1 IU/kg) was injected into the abdominal cavity 
and blood glucose was measured at time points 0, 15, 30, 60, 90, 120, and 180 minutes 
and AUC calculated as above. 
TBARS and urinary ferulic acid analysis 
Urinary thiobarbituric acid-reactive substances (TBARS) were measured using a 
previously described method (154).  
Urinary ferulic acid was measured by HPLC after deconjugation using a modification of 
the method of Bunzel et al. (155) Briefly, ferulic acid was deconjugated by mixing 5% of 
24 h collected rat urine with the same volume of 1 M sodium acetate buffer (pH 4.9), 300 
L of sulfatase solution (Sigma, S9626-10KU, ST. Louis, MO), and 100 L of 0.1 
mg/mL alpha coumaric acid solution (in 50% aqueous methanol). The mixture was 
incubated 37 °C for 3 h. The reaction was stopped with concentrated hydrochloric acid 
0.3 mL and ferulic acid extracted with a total of 4 mL ethyl acetate (2 mL, 1 mL, 1 mL). 
The pooled ethyl acetate phases were extracted with 5 mL of 5% sodium hydrogen 
carbonate (2 mL, 2 x 21.5 mL) and phases separated by centrifugation. The combined 
sodium hydrogen carbonate phases were acidified with 0.5 mL of concentrated 
hydrochloric acid until the pH was <2, and then extracted with 3 x 2.5 mL ethyl acetate. 
42 
 
The ethyl acetate phases were collected and dried under nitrogen. The dried extract was 
reconstituted in 200 L 50% methanol and 1:5 diluted for HPLC analysis. 
Quantification of ferulic acid was achieved using a Shimadzu HPLC system with auto 
sampler and SPD-M20A PDA detector. HPLC conditions are as follows: A Luna Phenyl-
Hexyl column (250 x10 mm; 4.6 µm particle size) was used for separation at a flow rate 
of 1 mL/min and temperature of 45 C. Mobile phases were 0.1 mM trifluoroacetic acid 
(TFA) (mobile phase A), 90% methanol/10% TFA (mobile phase B) and 90% 
acetonitrile/10% TFA (mobile phase C). The following gradient program was used (156): 
87% A and 13% C for 10 min; change over 10 min to 77% A, 3% B, and 20% C; change 
over 5 min to 70% A, 5% B, and 25% C; and finally change over 5 min to 25% A, 25% 
B, and 50% C. Detection wavelengths were 280 and 325 nm. 
 
Liver lipids and cholesterol 
Liver lipids were extracted with organic solvents using the method of Fölch et al. (157). 
The solvent was evaporated under nitrogen, and lipids determined gravimetrically. Liver 
cholesterol concentrations were determined enzymatically as previously described by 
Gallaher et al. (158) and fecal bile acids extracted and purified by the method of Locket 
and Gallaher (159) and quantified  using the method of Sheltawy (160).  
Statistical analysis  
The results were analyzed by ANOVA using the SAS statistical program (SAS 9.3, SAS 
Institute, Cary, NC). The group means were compared by Duncan’s multiple range test 
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and comparison of fat mass % between the obese control and whole wheat groups was 
done using Student’s t-test. Final body weight of the obese control and whole wheat 
groups was compared using Student’s t-test. Statistical significance was taken at p<0.05. 
Results  
Whole wheat and milling fractions do not alter body weight and food intake 
At the end of 4 weeks, the ZDF groups had significantly greater body weight compared to 
the lean group, as expected due to the animal model. However, there were no significant 
differences in weight gain among the ZDF groups (Table 2). Additionally, while the ZDF 
groups did have a greater mean food intake than the lean group, there were no significant 
differences in food intake among the ZDF groups (Table 2). 
Whole wheat produces greater fermentation 
Rats fed the whole wheat diet showed a significant decrease in cecum pH compared to 
the obese control, suggesting greater fermentation of this diet (Table 2). The cecum 
weight was significantly greater in the wheat based diets compared to the obese control 
except for the wheat bran group (Table 2). Among the wheat diet groups, the whole 
wheat showed a significantly greater cecum weight compared to the other wheat diets, 
further suggesting greater fermentation in this group. 
Whole wheat, but not milling fractions, reduce fat mass % 
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The obese control had greater epididymal, inguinal, and retroperitoneal plus perirenal fat 
pad weights compared to the lean group, as expected, but there were no significant 
differences among the ZDF groups in fat pad weights (Table 2).                                                                  
Likewise, a DEXA scan did not show significant differences in fat mass or lean mass 
percentage among the ZDF groups (Table 2). However, when compared by Student’s t-
test, the whole wheat group showed a significant decrease in fat mass percentage 
compared to the obese control (p=0.025).  
Whole wheat and wheat milling fractions reduce insulin resistance. 
A meal tolerance test was conducted at week 1 to examine the effect of the diets on the 
uptake of glucose and the insulin response to the diet. There were no differences in the 
plasma glucose AUC during the meal tolerance test between the obese control and the 
wheat milling fraction diet groups, although wheat bran did have a significantly greater 
AUC compared to the high wheat germ (Table 2).  The obese control group had a 
significantly greater insulin AUC than the lean control but there were no differences 
among the ZDF groups in the insulin AUC.  
After 3 weeks on the experimental diets, the fasting plasma glucose concentration of the 
whole wheat diet and refined wheat groups was significantly less compared to the obese 
control group while wheat bran, wheat germ, and high wheat germ were not different 
(Table 2).  
During the GTT at week 3, all wheat diets, except for wheat bran, had a reduced plasma 
glucose AUC compared to the obese control group (Table 2). Similarly, during an ITT, 
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also performed at week 3, the plasma glucose AUC was significantly lower in all ZDF 
wheat diet groups compared to the obese control (Table 2).  
A greater kidney weight as a percentage of body weight is considered a marker of poor 
blood glucose control (161). The kidney weight percentage was lower in the lean group 
compared to the ZDF groups, but there were no differences among the ZDF rats (Table 
2). 
Urinary 24 h TBARS was measured as a marker of whole body lipid peroxidation (Table 
2). Urinary TBARS was significantly greater in the obese control group compared to the 
lean control group. Urinary TBARS was significantly greater in the whole wheat, refined 
wheat, wheat bran, and high wheat germ groups than the obese control group, and whole 
wheat was greater than all other groups except high wheat germ.  
Plasma adiponectin, an adipokine that is generally inversely proportional to body fat and 
insulin resistance, was in fact greater in the obese control compared to the lean group 
(Table 2). The whole wheat group had a significantly lower plasma adiponectin 
concentration compared to the obese control whereas the individual wheat milling 
fraction groups were not different from the obese control group.  Resistin, another 
adipokine, is known to increase in models of obesity and T2D and has been suggested to 
be a link between obesity and insulin resistance (162). Plasma resistin was greater in the 
obese control group compared to the lean group. Although there were no differences 
among the ZDF groups, plasma resistin in the whole wheat and wheat milling fraction 
groups did not differ from the lean group (Table 2).  
Fatty liver is reduced with whole wheat and wheat milling fractions. 
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The liver weights of the lean group were significantly less than the ZDF groups, yet there 
were no differences among the ZDF groups (Table 3). The whole wheat and wheat 
fraction diets, however, had lower total liver lipids compared to the obese control.  
Total liver cholesterol concentration was significantly lowered in the wheat bran, germ, 
and high germ groups compared to the obese control, whereas the whole wheat and the 
refined wheat only showed a trend in decrease (Table 3). Liver free cholesterol 
concentration was not different among the ZDF groups. There was no difference in bile 
acid excretion between the obese control and lean groups, yet among the wheat groups 
the whole wheat and wheat bran groups had significantly greater fecal bile acid excretion 
compared to both the lean and obese control groups (Table 3). Fecal bile acid excretion 
did not correlate with liver cholesterol concentration (r2 =0.05, p = 0.67). 
Whole wheat and wheat germ groups had the greatest absorption of ferulic acid 
Ferulic acid, a phenolic acid found in wheat, has been suggested to slow the progression 
of diabetic complications (135, 163). The whole wheat group had the greatest intake of 
total ferulic acid followed by wheat bran, high wheat germ, refined wheat and, lastly, 
wheat germ (Figure 1). As there were differences in the relative concentration of total and 
free ferulic acid in the wheat diets, the daily intake of free ferulic acid was slightly 
different. The refined wheat group had the greatest free ferulic acid intake, followed by 
whole wheat, high wheat germ, wheat bran, and wheat germ (Figure 1). Urinary excretion 
of ferulic acid, a measure of ferulic acid absorption, mirrored the concentration present in 
the individual diets, with whole wheat having the greatest urinary ferulic acid excretion, 
followed by bran, high wheat germ, refined wheat and, lastly, wheat germ.  
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Discussion 
There is considerable epidemiological evidence indicating that consumption of whole 
grains, of two or three servings per day, in comparison to more refined grains, are 
associated with a lower risk of obesity (164, 165) (decrease in body weight and a change 
in body composition) and type 2 diabetes (85, 149),  although there are also studies that 
show no effect (166). When wheat is milled, the bran and germ are removed, and most of 
the dietary fiber, vitamins, minerals, essential fatty acids, and phytochemicals are lost. It 
is unknown which milling fraction of the whole wheat, the bran or the germ, may be 
responsible for the putative health benefits. Therefore, we investigated the effect of whole 
wheat and its individual milling fractions, endosperm, bran, and germ, on parameters of 
glucose control, insulin resistance, adiposity, and fatty liver using an animal model of the 
initial stages of diabetes with obesity, the ZDF rat. 
After 5 weeks consuming the diets, there were no differences in body weight or fat pad 
weights among the ZDF groups, suggesting that neither whole wheat nor its bran or germ 
milling fractions were more effective than endosperm (refined wheat) at minimizing 
weight gain and body fat. Although whole grain intake is highly associated with a lower 
body weight in observational studies (95, 167), a direct relationship is not supported in 
clinical trials (102, 103). In the present study, no decrease in body weight was observed 
with consumption of whole wheat, yet a decrease in body fat percentage in the whole 
wheat group compared to the obese control was found by DEXA scanning. These 
findings are similar to a study conducted by Kristensen et al. (99), in which overweight or 
obese women fed isoenergetic diets containing either refined or whole wheat for 12 
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weeks showed no difference in body weight but did have a decrease in body fat 
percentage by DEXA, implying a change in body composition. A study in women 
conducted over 20 months reported that for every 1g increase in total fiber consumed a 
day body weight decreased by 0.25 kg and body fat by 0.25% (168). However, in the 
present study all diets were isofibrous, so changes in dietary fiber consumption does not 
explain the reduction in body fat experienced by the whole wheat group, as measured by 
DEXA scanning. A possible reason as to why no differences in the fat pad weights were 
seen could be the greater variability in fat pad weights compared to DEXA scanning, as a 
result of the challenge in precise removal of fat pads in these extremely obese animals. 
There were no differences in body weight or body fat percentage with the milling 
fractions compared to the obese control. This is consistent with other studies reporting 
that wheat bran fed to obese Zucker rats did not alter either final body weight or fat pad 
weight (169). Although glucose intolerant subjects given wheat bran as a supplement to 
their diet experienced a slight but statistically significant decrease in body weight (170), 
body weight in patients with diverticular disease experienced no change in weight with 
wheat bran consumption (171).  
A possible explanation for the reduced fat mass percentage in the whole wheat group 
could be the effect of fermentation. After 5 weeks on the diets, the whole wheat diet 
group showed a significant decrease in pH level and greater cecum weight, suggesting 
greater fermentation of the diet. In a similar study pigs were fed different whole grains, 
including whole wheat, and saw an increase in fermentation which was believed to be 
due to fermentation of the soluble fiber arabinoxylans present in cereals (172). Adam et 
al. (88) also saw decreased pH and increased cecum weight in rats fed whole and refined 
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wheat, but not with wheat bran, which can be attributable to the small amounts of soluble 
fiber present in bran. Fermentation increases production of short chain fatty acids 
(SCFA), which have been shown to increase the release of the satiety peptides PYY and 
GLP-1 in some cases (173) but not others (130), depending on the type of fermentable 
fiber.  
The reduction in fasting blood glucose and glucose AUC during an ITT and GTT 
suggests that all wheat diets led to a significant improvement in glucose control and 
reduction in insulin resistance compared to the obese control group. However, there was 
only a trend for a lower GTT AUC and fasting blood glucose in the wheat bran group 
compared to the obese control group. A decrease in kidney weight as a percentage of 
body weight is considered a secondary maker of blood glucose control (161). In this 
study, there were no differences in relative kidney weight among the ZDF groups, even 
though there was a decrease in insulin resistance in the whole wheat or wheat fraction-fed 
groups. It is interesting that both whole wheat and refined wheat were able to improve 
insulin resistance to the same degree compared the control diet. This result brings into 
question the recommendation to consume whole grains over refined grains to reduce the 
risk of diabetes. Several clinical trials that examined the effect of whole grains versus 
refined grains also did not show improved glucose control (100-102). The inconsistent 
findings of improved insulin resistance and decreased BMI with whole grain 
consumption in observational studies and the lack of such an effect in clinical trials may 
be due to factors that were not controlled for such as healthier lifestyles in general. 
Participants who ate more whole grains in observational studies may have a better diet 
and may be more physically active (174). We suggest that the greater insulin sensitivity 
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of the whole wheat and the refined wheat groups, compared to the obese control, is due to 
the type of starch present. The obese control diet contained only purified corn starch 
whereas the whole wheat and refined wheat contained mostly wheat starch. Unpurified 
wheat starch contains proteins and more complex starch granules compared to purified 
corn starch (175). This, along with small amounts of soluble dietary fiber in the form of 
arabinoxylans, could slow glucose absorption, which is known to reduce the progression 
of insulin resistance (176, 177). The differences between the wheat diets and the control 
diet, which used corn starch as the main carbohydrate source, maybe be due to 
differences in the ratio of amylose to amylopectin, as amylose has a lower glycemic 
index than amylopectin (117). The percent of amylose and amylopectin in wheat starch is 
25% and 75% respectively (178) whereas in corn starch it is 5% and 95% (124). 
Although wheat bran was able to decrease insulin resistance, as shown by the decreased 
AUC during the ITT, there was not a corresponding change in the GTT or fasting blood 
glucose. This is consistent with a well-controlled study by Jenkins et al. (104), who found 
that consumption of wheat bran for 3 months did not alter measures of blood glucose 
control.  
One characteristic of whole grains that has been suggested to improve insulin sensitivity 
is their low glycemic index. This is believed to improve glucose control by limiting large 
spikes in blood glucose and insulin (179). Interestingly, during the MTT in week 1, there 
was no difference in the AUC of the postprandial plasma glucose or insulin curves of the 
wheat diets compared to the obese control. This might suggest that the reduced insulin 
resistance observed in the wheat diets is not to be due to a lower glycemic index 
compared to the control diet. However, it may be that in this ZDF model the differences 
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in postprandial insulin and glucose caused by the wheat diets are too small to be observed 
from a meal tolerance test, but still result in improvements in glucose control by the end 
of 3 weeks of feeding.  
It is unclear why wheat germ and high wheat germ improve insulin sensitivity and 
glucose control. The effect of wheat germ on insulin resistance is not widely studied, but 
in a clinical trial by Cara et al. (105), subjects who consumed 30 g of wheat germ for 4 
weeks had no change in fasting blood glucose. There have been studies that suggest that 
particle size of the diet could be responsible for the differences in glucose control. It has 
been shown that larger particle sizes decrease postprandial glycaemia compared to 
smaller particle sizes (120, 180). However, a reduced glycemic response is not observed 
in all studies (121). In various animal studies it has been shown that food structure has an 
influence in gastric emptying, which reduces the rate of glucose entry into the 
bloodstream (180), therefore allowing circulating fatty acids to be used for energy (181). 
Increased circulating fatty acids are involved in the progression of peripheral and hepatic 
insulin resistance (182). Simply by not chewing food finely, whether the food is rice, 
potatoes or apples, will slow down glucose absorption, suggesting that the structure of 
food is more important than its composition (183). Larger particle sizes, such as wheat 
germ, have been shown to affect gastric emptying (184), however in this study a lower 
glycemic response was not observed and neither was it in other studies (185). Therefore, 
other explanations for the improved insulin resistance and glucose control are needed. 
There are data suggesting that wheat germ supplementation may reduce total lipid 
absorption (186) which could indirectly improve insulin resistance through decreased 
body fat. However, as we saw no difference in fat mass %, it is unclear how this may 
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have affected insulin resistance. There was no additive effect of the wheat fractions on 
glucose control because there was no difference between the wheat fraction groups and 
the whole wheat group. 
Adipokines released by adipose tissue are associated with insulin resistance and fat mass. 
Circulating adiponectin, an adipokine that is generally inversely proportional to body fat, 
is generally reduced during insulin resistance (32, 187). Obese ZDF rats normally have 
lower concentrations of adiponectin compared to their lean counterparts (188), but in this 
study the obese control had significantly greater adiponectin concentrations compared to 
the lean rats. It is unclear why the obese control group would have greater adiponectin 
concentration compared to the lean and whole wheat groups, even though they have 
greater insulin resistance.  
Resistin is released by adipose tissue (189) and has shown to be increased in animals with 
high body fat compared to lean animals (35). High plasma resistin levels have been 
associated with insulin resistance in humans (190), however other studies show no 
association (191). There was no significant difference in resistin levels among the ZDF 
groups, although there was a trend toward a decrease in the wheat groups compared to the 
ZDF control. 
Oxidative stress can be classified as an imbalance between the formation of reactive 
oxygen species and the ability for the body to eliminate these reactive species that can 
cause damage to cellular macromolecules. These reactive species can trigger 
inflammatory pathways such as NFβ and JNK, which can activate kinases that interrupt 
insulin signaling, causing insulin resistance and T2D (192). A buildup of free radicals can 
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attack lipids, particularly unsaturated fatty acids, and cause peroxidation products to 
accumulate. Urinary 24 h TBARS were measured as a marker of whole body lipid 
peroxidation. Increased urinary TBARS is typically associated with greater insulin 
resistance, yet in this study, all wheat diets, except for wheat germ, had greater TBARS 
excretion compared to the obese control. It is unclear why the groups with lower insulin 
resistance had greater oxidative stress. Due to urine being collected in non-fasting rats, it 
is possible that other compounds in the wheat may have influenced the results of the 
TBARS assay. 
NAFLD typically accompanies obesity and T2D and is characterized by an accumulation 
of triglyceride lipid droplets in hepatocytes. Increased fatty acid flux from enlarged 
adipose tissue as well as increased de-novo lipogenesis and/or increased fatty acid 
oxidation during hepatic insulin resistance, contributes to the accumulation of lipids (71). 
There was no difference in liver weight between the obese control and wheat groups, 
however, all whole wheat and wheat fraction diets had lower total liver lipids compared 
to the obese control, indicating a reduction in fatty liver. This is supported by previous 
studies, where the addition of whole wheat, refined wheat or wheat bran to the diet of rats 
reduced liver triglycerides (88). As mentioned above, a lower glucose and insulin 
response, either through small amounts of soluble fiber, the structure of starch granules, 
or particle size, could be the explanation. There is selective insulin resistance in the liver, 
where insulin fails to inhibit gluconeogenesis while at the same time is able to upregulate 
lipogenesis (74). This is in agreement with our observation of reduced glucose control, 
probably in part through increased gluconeogenesis, with greater fatty liver in the obese 
control group compared to the wheat diets. The decrease in total liver cholesterol 
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concentration in wheat bran, germ, and high germ groups may be due to greater fecal bile 
acid excretion, which was also greater in these groups. Bile acids are synthesized from 
cholesterol in the liver and therefore an increase in the excretion of bile acids results in 
the decrease of cholesterol in the liver (193) (194). This was not the case in the whole and 
refined wheat groups where there was no difference in liver cholesterol yet there was 
greater bile acid excretion. Previous studies show that cholesterol is decreased with 
soluble fiber consumption (195) and wheat fiber, which is mostly insoluble, has no effect 
(196). Another possible explanation for the decrease in liver cholesterol in the wheat 
germ groups could be the relatively high concentration of plant sterols. Due to the higher 
affinity of plant sterols for incorporation into the micelles, compared to cholesterol, there 
is reduced absorption of cholesterol from the intestinal lumen and therefore greater 
excretion in the feces (144). It appears that neither fiber content, which was mostly 
insoluble and balanced among all groups, nor bile acid excretion can entirely explain the 
decrease in total and free liver cholesterol.  
Whole wheat contains high amounts of ferulic acid, a phenolic compound that may have 
a beneficial role in reducing body weight (140) and slowing the progression of T2D 
(135). Ferulic acid is able to form a stable radical, allowing it to scavenge reactive 
oxygen species (ROS) produced as byproducts in the electron transport chain. ROS have 
been implicated in insulin resistance by interfering with normal insulin signaling 
pathways and triggering inflammation in the muscle and liver (139). Ferulic acid is 
mostly bound to the cell wall of wheat and therefore is only slightly bioavailable due to 
limited release by gut microflora (138). The whole wheat and wheat bran groups, which 
had the greatest amount of ferulic acid absorbed, based on urinary ferulic acid excretion, 
55 
 
showed improvements in glucose control and insulin resistance. On the other hand, this 
may not be due to ferulic acid absorption because the wheat germ, which showed little 
urinary ferulic acid excretion, also showed decreased insulin resistance. In fact, wheat 
bran, which is the milling fraction containing the most ferulic acid, did not cause a 
difference in GTT AUC or fasting blood glucose. These results do not support the 
suggestion that insulin resistance is altered by ferulic acid in wheat as all the wheat diets 
showed an improvement in glucose control.  
In conclusion, the consumption of whole wheat and its milling fractions for 5 weeks 
improved glucose control and decrease insulin resistance and fatty liver in ZDF rats. 
Whole wheat, however, was no more effective at improving these parameters than its 
individual milling fractions. These effects do not appear to be due to changes in plasma 
adiponectin concentration or absorption of ferulic acid. It is possible that small amounts 
of soluble fiber in the whole wheat and refined wheat fraction may be responsible for the 
positive health benefits, but it is unclear why the bran and germ fractions were also 
equally effective. Thus, in this short term study, none of the wheat milling fractions stand 
out as responsible for the effects seen with consumption of whole wheat. The results of 
this study suggest that individual milling fractions of wheat are just as effective in 
improving insulin resistance and fatty liver as whole wheat. 
Advantages and limitations of the study and future directions  
This study has many advantages, such as a well-controlled study design, use of a food 
source in a form that is normally consumed in the population rather than a food extract, a 
balanced macronutrient composition, and an examination of each milling fraction in 
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addition to whole wheat. To our knowledge, this is the first study to do this. That said, 
there are also some limitations. One unavoidable limitation was the length of the study. It 
would have been helpful to prolong the feeding trial to see long-term effects of the diets, 
but due to the characteristics of the animal model, the rats would have been in an 
advanced state of diabetes and it would have been impossible to see changes brought on 
by the diet. Even in this short term study the animals may have been too diabetic and 
obese, making it more difficult to detect large changes between the groups. Finally, as 
with all animal studies, to what degree the results can be extrapolated to humans is 
uncertain.  
Following the results acquired from this study, future research can be directed in various 
ways to further explore possible mechanisms of whole wheat and its milling fractions. 
First, the effect of particle size on postprandial glucose curve could be examined by 
milling whole wheat into different particle sizes and observing whether there is a 
difference in the parameters we studied. Another approach could be varying the ratios of 
amylose to amylopectin using different wheat varieties to determine its effects on insulin 
resistance and glucose control. Using a different animal model, such as the high fat-fed 
rat, and feeding for a longer period of time could also be helpful in finding small 
differences that may not have been detectable with the ZDF model. 
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Table 2-1. Diet composition  
Nutrient 
(g/kg) Control 
Whole 
wheat flour 
Refined 
wheat flour 
Wheat 
bran 
Wheat 
germ 
High 
Wheat 
Germ 
Flour  0 650 542.75 0 0 0.00
Milling 
fraction 
0 0 0 94.25 16.25 153.75
Sucrose 40 40 40 40 40 40.00
Corn Starch 506.95 5.4 59.35 463.45 498.08 424.50
Soybean Oil 120 105.50 100.18 114.29 118.17 105.00
Casein 200 136.28 149.6 188.31 195.92 164.00
Cellulose 81.3 11.06 56.36 47.93 79.81 61.00
Mineral Mix 35 35 35 35 35 35
Vitamin Mix 10 10 10 10 10 10
L-Cystine 3 3 3 3 3 3
Cholesterol 1.25 1.25 1.25 1.25 1.25 1.25
Choline 
Bitartrate 
2.5 2.5 2.5 2.5 2.5 2.5
BHT 0.014 0.014 0.014 0.014 0.014 0.014
Total Weight 1000.014 1000.014 1000.014 1000.014
1000.014 1000.014
              
% CHO 54.70 53.86 52.65 56.35 54.57 53.66
% Protein 20.00 18.90 18.78 20.00 20.00 20.26
% Fiber 8.13 6.83 7.05 8.13 8.13 7.51
% Fat 12.00 12.00 10.84 12.00 12.00 12.23
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Table 2-2. Measures of body weight, food intake, tissue weights, cecum pH, glucose 
control 
Parameters 
Negative 
Control 
Positive 
Control 
Whole 
Wheat 
Refined 
Wheat 
Wheat Bran 
Wheat 
Germ 
High 
Wheat 
Germ 
Weight Gain 
(g) 
104.6 ± 
5.8a 
158.4 ± 
3.1bc 
148.7 ± 
6.3b 
153.1 ± 3.8
bc 
158.4 ± 3.7 
bc 
161 ± 3.6c 160.8 ± 
2.7c 
Average food 
intake (g) 
16.7 ± 
0.6a 
22.7 ± 
1.04b 
22.7 ± 
0.41b 
23.1 ± 
0.53b 
23.1 ± 0.7b 24.5 ± 
0.82b 
23.4 ± 
0.33b 
Cecal pH 6.8 ± 
0.07b 
6.8 ± 0.07
b 
6.2 ± 0.11a 6.9 ± 0.04 b 6.8 ± 0.08 b 6.8 ± 0.09 b 6.7 ± 0.05 b 
Cecum weight 
(g) 
0.389 ± 
0.007bc 
0.337 ± 
0.010a 
0.525 ± 
0.021d 
0.439 ± 
0.014c 
0.374 ± 
0.020ab 
0.390 ± 
0.012b 
0.410 ± 
0.018bc 
Epididymal 
fat pad weight 
(g) 
0.405 ± 
0.011a 
1.149 ± 
0.055b 
1.144 ± 
0.032bc 
1.091 ± 
0.015b 
1.154 ± 
0.031bc 
1.129 ± 
0.021bc 
1.149 ± 
0.021c 
Retroperitone
al + perirenal 
fat pad weight 
(g) 
0.492 ± 
0.029a 
1.467 ± 
0.027b 
1.464 ± 
0.052 b 
1.471 ± 
0.0528b 
1.513 ± 
0.049b 
1.469 ± 
0.040b 
1.583 ± 
0.023b 
Inguinal fat 
pad weight (g) 
0.672 ± 
0.031a 
3.443 ± 
0.201b 
3.146 ± 
0.184 b 
3.293 ± 
0.162 b 
3.236 ± 
0.194 b 
3.442 ± 
0.120 b 
3.560 ± 
0.155 b 
Body fat %2 18.95 ± 
0.56a 
55.15 ± 
1.31b 
51.75 ± 
0.72 b* 
53.64 ± 
1.27 b 
55.38 ± 
1.95 b 
55.7 ± 1.66
b 
54.89 ± 
2.09 b 
Lean mass %2 81.027 ± 
0.55b 
44.88 ± 
1.29a 
48.20 ± 
0.71 a 
46.378 ± 
1.26 a 
44.60 ± 
1.97 a 
44.33 ± 
1.69 a 
45.13 ± 
2.09 a 
Fasting blood 
glucose week 
98.1 ± 
4.2a 
149.6 ± 
6.4c 
125.6 ± 
5.3b 
121.3 ± 
4.8b 
136.1 ± 
4.7bc 
134.1 ± 
3.2b 
136.2± 
6.4bc 
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1Values represent mean ± SEM, n=10-12, except where noted. Values within a row that 
do not share a common superscript are significantly different, p<0.05. 
2Measured at 4 weeks. 
3 (mg/dL) 
AUC GTT 
(x103) 
18.76 ±  
0.33a 
32.34 ± 
1.238c 
27.54 ± 
1.45b 
28.19 ± 
0.68b 
30.16 ± 
1.28bc 
28.62 ± 
0.9b 
29.13 ± 
1.16b 
AUC ITT 
(x103) 
8.26 ± 
0.92a 
22.47 ± 
0.8c 
19.1 ± 
0.79b 
19.61 ± 
0.64b 
19.91 ± 
0.79b 
20.04 ± 
0.55b 
19.24 ± 
0.67b 
AUC MTT 
Glucose 
response 
(x103) 
26.94 ± 
0.34a 
32.99 ± 
0.95bc 
30.48 ± 
1.68bc 
31.98 ± 
0.91bc 
33.74 ± 
1.34 c 
32.57 ± 
0.74bc 
29.84 ± 
1.21ab 
AUC MTT 
Insulin 
response 
105.51 ± 
15.67a 
804.72 ± 
114.35bc 
758.09 ± 
125.79bc 
862.73 ± 
134.07c 
817.65 ± 
132.30bc 
863.48 ± 
101.36c 
530.98 ± 
125.41b 
Kidney 
weight, as a 
percentage of 
body weight 
(g/100g BW) 
0.703 ± 
0.013b 
0.622 ± 
0.059a 
0.671 ± 
0.017 a 
0.630 ± 
0.016 a 
0.618 ± 
0.019 a 
0.606 ± 
0.015 a 
0.622 ± 
0.217 a 
TBARS 
(g/24h) 
3.586 ± 
0.384a 
6.002 ± 
0.361b 
12.183 ± 
1.158e 
8.367 ± 
0.771c 
8.827 ± 
0.585cd 
8.111 ± 
0.622bc 
10.810 ± 
0.899de 
Adiponectin 
(g/ml) 
28.559 ± 
1.61a 
35.668 ± 
2.448c 
29.228 ± 
2.061ab 
37.394 ± 
2.506c 
32.270 ± 
2.292abc 
36.789 ± 
2.409c 
34.518± 
3.047bc 
Resistin 
(ng/ml) 
16.6± 
1.29a 
20.4±0.84
b 
18.8±1.1ab 18.6±1.06ab 18.3±1.33ab 18.31±0.94
ab 
18.7±1.04ab
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*Significantly different from obese control by Student’s t-test. 
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Table 2-3. Liver weights, liver lipids, liver cholesterol bile acid excretion 
Parameter Negative 
Control 
Positive 
Control 
Whole 
Wheat 
Refined 
Wheat 
Wheat 
Bran 
Wheat 
Germ 
High 
Wheat 
Germ 
Liver 
weight (g) 
7.421 ± 
0.276a 
15.058 ± 
0.625b 
15.766 
± 0.062b 
14.488 ± 
0.437b 
14.527 ± 
0.740b 
14.116 ± 
0.619b 
14.606± 
0.913b 
Total liver 
lipids 
(mg/liver) 
527.0 ± 
43.8a 
2583.5 ± 
294.5c 
1844.2 
± 120.4b 
1694.9 ± 
152.4b 
1491.1± 
157.9b 
1605.7 ± 
180.3b 
1479.9 
± 
170.9b 
Total liver 
cholesterol 
(mg/g) 
7.003 ± 
0.372a 
13.361 ± 
0.922d 
10.86 ± 
0.733bcd 
11.05 ± 
0.969cd 
8.513 ± 
0.679ab 
9.454 ± 
0.627abc 
6.939 ± 
0.677a 
Free liver 
Cholesterol 
(mg/g) 
2.029 ± 
0.02b 
1.875 ± 
0.05ab 
1.701 ± 
0.04a 
1.862 ± 
0.08a 
1.74 ± 
0.041a 
1.87 ± 
0.05ab 
1.77 ± 
0.05a 
Bile acid 
excretion 
(mg/day) 
3.262 ± 
0.119ab 
2.915 ± 
0.178a 
5.586 ± 
0.525c 
3.831 ± 
0.156b 
5.022 ± 
0.406c 
3.970 ± 
0.179b 
3.994 ± 
0.148b 
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Figure 2-1. Daily total and free ferulic acid intake  
Values represent mean ± SEM, n=10-12. Values that do not share a common superscript 
are significantly different, p<0.05. Measured at 4 weeks. 
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Figure 2-2. Urinary excretion of ferulic acid over 24 h 
Values represent mean ± SEM, n=10-12. Values that do not share a common superscript 
are significantly different, p<0.05. Measured at 4 weeks. 
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Appendix	1:	Liver	Lipid	Extraction		
 
1) Weigh out ~1.00 gram of liver tissue and transfer to homogenizing tube. 
 2) Add 10 mL Chloroform:MeOH (2:1). 
 3) Homogenize for ~15-20 seconds. 
 4) Filter homogenate through a #1 Whatman filter paper into a glass screw top tube. 
 5) Rinse homogenizer with 15 ml Chloroform:MeOH (2:1) and pick out any tissue 
trapped on probe. 
 6) Pour rinse through filter paper into tube. 
 7) Wash filter paper with an additional 5 ml Chloroform:MeOH (2:1). 
 8) Add 6 ml 0.9% NaCl to filtrate.  This represents a volume of 0.2 times the volume of 
Chloroform:MeOH used. 
 9) Vortex to mix aqueous and nonaqueous phases. 
10) Centrifuge for 1 minutes at 750 RPM to separate phases.  Be careful about placement 
of tubes in the centrifuge – when rotor spins, long tubes may break as they tilt.  
Alternatively, let the tubes stand until phases separate. 
11) Remove aqueous upper phase with a transfer pipet and discard. 
12) Gently layer 3 ml of MeOH:H2O (1:1).  Rinse sides of tubes while adding the 
MeOH:H2O. 
13) Remove this upper phase with a transfer pipet and discard. 
14) Transfer the extracted lipid in Chloroform:MeOH (2:1) and transfer rinse to lipid vial. 
15) Evaporate Chloroform under N2 gas. (Gravimetric Step) 
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16) Reconstitute the fat with a set volume for all samples (10 ml) in Chloroform:MeOH 
(2:1). 
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Appendix	2:	Enzymatic	Cholesterol	Assay	
 
Reagents 
1) 50 mM Sodium Phosphate, Dibasic (MW = 141.96).  Make 1 L, pH 6.9 
    (7.1 g/L). 
2) Stock Phenol Reagent: 500 ml 
    Dissolve 3.8 g Phenol crystals in 400 ml Phosphate Buffer.  Adjust volume to 500 ml 
with Phosphate Buffer.  Store at 4degrees? C (up to 1 month). 
3) Stock Mixed Reagent: 500 ml 
    Dissolve in 400 ml Phosphate Buffer: 
        0.203 g 4-aminoantipyrine 
        1.292 g Sodium cholate 
        7.46 g Potassium chloride 
        1.0 ml Triton X 
    Adjust volume to 500 ml with Phosphate Buffer.  Store at 4 C (up to 1 month). 
4) Working Reagent: (shelf life: 3-4 days) 
                                         (UI)/30mL              (UI)/100 mL                  (UI)/200 mL 
     Reagent                  (mL)   (mL)    (mL) 
     Stock Mixed Reagent 15   50   100  
     Stock Phenol   15   50   100 
     Cholesterol Oxidase (UI) 7.5   25    50 
     Cholesterol Esterase (UI) 7.5   25   50 
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     Peroxidase (UI)             375   1250   2500 
    Store in ice bath until ready to use. 
****NOTE**** For free cholesterol assay, omit esterase 
 
A) Standard Curve: 
    Use 1 mg/ml concentration of cholesterol in Chloroform:MeOH (2:1).  Use 0, 5, 10, 
15, 20, and 25 l concentrations (depends on cholesterol in sample). 
    Add 50 l Triton X-100/Acetone to each tube, Vortex. 
    Dry under N2 gas.     (Triton Sol'n = 1.5 g Triton in 10 mL acetone) 
 
B) Samples:  Total Cholesterol: 10 l assayed 
              Free Cholesterol: 50 l assayed 
    Add 50 l Triton X-100/Acetone. 
    Dry solvent under N2 gas 
 
C) Assay:  Add 100 l ddH2O to each tube, Vortex. 
   Add 1 ml Working Reagent/sample, Vortex. 
    Incubate at 37º C for 10 min.  Cool to room temperature. 
    Read absorbance at 500 nm. 
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Appendix	3:	Assay	of	Total	Bile	Acids	
 
References: 
1. MacDonald, Ian (1976) Clin. Biochem. 9, (3) 153-154, Enzymatic Analysis of Bile 
Acids. 
2. Locket, P.L., Gallaher, D.D. (1989), Lipids 24 221-223 
3. Bile Acid Assay III (Sheltawy, 1975, Determination of faecal bile acids by an enzymic 
method) 
Materials: 
Equipment 
Spectrophotometer 
Waterbath: Temp. approx. 37 C 
Reagents 
0.01M Cholic Acid in 100% MeOH for std. Curve 
3-Hydroxysteroid dehydrogenase; Sigma No. H-1506 from  
 Pseudomonas testosteroni; Need ~1.5 units enzyme/mL phosphate buffer, but          
could go down to 1.25 units/mL  
-     0.01M Phosphate buffer; use sodium phosphate monobasic, pH 7.2 
-     0.05M CAPS buffer, adjust pH to 10.8 w/ NaOH 
-     NAD (β-nicotinamide adenine dinucleotide), use 1.25mg NAD/ml CAPS                                    
buffer.  Use NAD soln the day it is made 
-     Methanol, reagent grade 
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PROCEDURE 
Generation of Standard Curve 
A standard curve must be generated each day that sample bile acids are run.  This is 
because the quantity of bile acids in each sample is calculated from the equation of the 
regression line generated by the standard curve.  This equation will vary with minor 
changes in the concentration of NAD substrate and enzyme.  Because new NAD soln 
must be made with each assay a new std. curve must also be run.  No more than 30 
samples should be run per one standard curve. STANDARD CURVE SHOULD BE 
DONE IN TRIPLICATE. 
 
1. Label small test tubes with vol. of cholic acid std. to be added.  Use std. volumes of 0, 
10, 20, 30, 40, and 50ul. 
2. To each tube add: 
100% MeOH to give a total MeOH volume (Std. vol. + MeOH) of 100 l. (i.e. to tubes 
labelled 0 add 100 ul MeOH) 
Cholic acid standard in MeOH, volumes listed in step 1 
1.25 ml NAD in CAPS buffer 
150 l Enzyme solution 
3. Cap tubes with corks or cover the rack with parafilm tightly and vortex. 
4. Incubate the tubes in a water bath at approx. 37 |C for 20 min. 
5. Remove tubes from water bath and allow them to adjust to room temperature  for about 
5 min. 
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Sample Preparation 
After you have determined that the bile acid assay works, (a standard curve has been run 
independently and proves linear) samples should be prepared for bile acid analysis. Run a 
standard curve each day that you run samples. 
1. Resolubilize partially purified bile acids in 0.5ml 100% MeOH. 
2. Add to assay tubes 
50 l 100% MeOH 
50 l sample   
1.25ml NAD in CAPS 
150 l Enzyme soln 
3. Cap samples, vortex then incubate samples with standards. 
*Note: if absorbance is too high or low adjust sample volume assayed to bring 
absorbance to around 1. 
 
Spectrophotometric analysis 
 Set up a program on the computer attached to the spec for this assay.  Note the 
wavelength of absorbance is 340 nm.  Add a couple blank analysis samples at end for 
repetition if needed. 
Zero the instrument using double distilled water.  Use the 0 level bile acid standard as 
your blank. 
Run standards followed by samples.  Rerun the standard blanks at end of run. 
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Calculation of Bile Acid Quantity 
1. Convert l Std. to nmoles B.A. 
2. Run a regression of nmoles B.A. against Corrected Absorbance. 
Corrected Absorbance = (Abs. 1 - Abs. 2)/2 - Ave Abs. Blank 
3. Y-intercept should be close to zero, r2 = 0.99 
4. From the corrected absorbances of samples (ave. of 2 sample reps - blank) calculate 
nmoles B.A. using regression equation. 
July 28, 1992, June 2004 
C. Gallaher/DDG 
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Bile Acid Extraction and Purification 
 
Reference:  Locket, PL & Gallaher, DD (1989) Lipids 24, 221-223. 
MATERIALS 
Methanol 
Ethanol, absolute 
Chloroform 
Petroleum Ether 
Solid phase extraction columns, reverse phase C18 
Screw-capped tubes (check to make sure they seal tight) 
Bath sonicator 
Heating block 
Nitrogen gas 
 
SOLUTIONS 
Ethanol, 80 % 
Add 20 parts of distilled water to 80 part of absolute ethanol.  Store at room temperature. 
Chloroform/methanol 
Mix equal volumes of chloroform and methanol.  Store at room temperature. 
 
PROCEDURE  
Extraction 
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1. Weigh approximately 100 mg of tissue or feces into a screw cap tube (20 X 125 mm or 
similar size).  Record the exact weight. 
2. Add 2 ml of absolute ethanol to each tube. 
3.  Sonicate the capped tubes in a bath sonicator for 30 min. 
3.  Place the tubes in a heating block and reflux at 100°C for 15 min. 
4.  Centrifuge the tubes at approx. 1,500 X g for 10 min.  Transfer the supernatants to 
screw capped tubes. 
5.  Suspend the pellets in 2 ml of 80% ethanol, reflux for 15 min in the heating block, and 
centrifuge as in step 4.  Again transfer the supernatants to the screw capped tubes. 
6.  Suspend the pellet again in 2 ml of chloroform/methanol, reflux for 15 min in the 
heating block, and centrifuge as in step 4.  Transfer the supernatants to the screw capped 
tubes. 
Suspend the pellet in 2 ml of chloroform/methanol, centrifuge as in step 4, and transfer 
the supernatants to the screw capped tubes. 
8. Evaporate the pooled supernatants to dryness with nitrogen gas under low heat 
(<60°C).  Store dried samples capped in the freezer until ready for partial purification. 
 
Partial Purification 
1. Remove the rack, if present, from inside the solid phase extraction (SPE) column 
processor.  Insert the SPE columns into the column processor and turn on the water 
aspirator.  Adjust the vacuum to about 5-10 mm Hg with the screw located on the 
vacuum arm closest to the processor (NOT the wing nut).   
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2. Solvate (activate) the columns by adding 4 ml of MeOH to each column.  Follow with 
4 ml of distilled water (DW).  Do not allow the columns to dry out if possible between 
solutions.  Stop the flow through the columns by releasing the vacuum by opening the 
wing nut. 
3. To tubes containing the dried tissue or fecal extract, add 0.6 ml MeOH and vortex to 
solubilize the bile acids.  Next add 2.4 ml DW to each tube and vortex again. 
4. Pour the solution from above through a solvated column and apply vacuum. 
5. When the level of solution in the columns drops to the frit, add 3 ml of DW. 
6. When the level of DW in the columns drops to the frit, add 3 ml of hexane. 
7. When the level of hexane has dropped to the frit for all columns, release the vacuum 
with the wing nut and carefully remove the cover of the SPE column processor.  Insert 
the rack with labeled tubes in the correct position to collect the column eluents. 
8. Add 3 ml MeOH to each column and turn on the vacuum.  The flow of MeOH through 
the column should be 2-3 ml/min.  The MeOH will elute the bile acids off the columns, 
which will then be collected in the tubes within the processor. 
9. After the flow through the columns stops, release the vacuum, remove the tubes, and 
evaporate the solution to dryness with nitrogen gas at low heat.   
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Appendix	4:	Urinary	Thiobarbituric	Acid	Reactive	Substances	
(TBARS)	Procedure	
 
Reference: Hye-Sung Lee, Lipids 27:124-128, 1992 
Reagents: 
 5% (w/v) Tri-chloroacetic acid (TCA). 5g to 100 ml H2O. 
 0.06 M Thiobarbituric acid (TBA). 0.8652g 2-thiobarbituric acid to 100 ml H2O. 
 
 Store stoppered reagents in cold room.  
 Before use, warm TBA solution in water bath (as the bath heats up) to return all 
precipitate to solution, then cool to room temperature. 
 
MDA Standard: 
 10-5 M  Malondialdehyde (MDA) 
 Synthesis of MDA 
 
1. Weigh 164.2 mg (1 mmol) malondialdehyde tetramethylacetal into a 100 ml glass 
stoppered Erlenmeyer flask. 
2. Add 100 ml 0.01 N HCl, stopper immediately and wrap the top with Parafilm. 
3. Heat in 50 C water bath for 1hr. 
4. Cool to room temperature in a dark place. 
5. Dilute with water to 10-5 M. 
            1 ml 10-2  M (as prepared) to 100 ml water = 10-4  M 
           10 ml 10-4  M to 100 ml water = 10-5 M. 
 
 MDA is very sensitive to light, store in the cold room in a flask wrapped in a foil. 
 Approximate shelf-life is one month. 
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Appendix	5:	Ferulic	Acid	
Urinary ferulic acid was measured by HPLC after deconjugation using a modification of 
the method of Bunzel et al. Briefly, ferulic acid was deconjugated by mixing 5% of 24 h-
collected rat urine with the same volume of 1 M sodium acetate buffer (pH 4.9), 300uL of 
sulfatase solution, and 100 L of 0.1 mg/mL alpha coumaric acid solution (in 50% 
aqueous methanol). The mixture was incubated 37 °C for 3 h. The reaction was stopped 
with concentrated hydrochloric acid 0.3 mL and ferulic acid extracted with a total of 4mL 
ethyl acetate (2mL, 1mL, 1mL). The pooled ethyl acetate phases were extracted with 5ml 
of 5% sodium hydrogen carbonate (2mL, 2x 21.5mL) and phases separated by 
centrifugation. The combined sodium hydrogen carbonate phases were acidified with 
0.5mL of concentrated hydrochloric acid until the pH was <2, and then extracted with 3 x 
2.5mL ethyl acetate. The ethyl acetate phases were collected and dried under nitrogen. 
The dried extract was reconstituted in 200uL 50% methanol and 1:5 diluted for HPLC 
analysis. 
Quantification of ferulic acid was achieved using a Shimadzu HPLC system with auto 
sampler and SPD-M20A PDA detector. HPLC conditions are as follows: A Luna Phenyl-
Hexyl column (250 x10mm; 4.6um particle size) was used for separation at a flow rate of 
1mL/min and temperature of 45 o C. Mobile phases were 0.1 mM trifluoroacetic acid 
(TFA) (mobile phase A),  90% methanol/10% TFA (mobile phase B) and 90% 
acetonitrile/10% TFA (moble phase C). The following gradient program was used (156): 
87% A and 13% C for 10 min; change over 10 min to 77% A, 3% B, and 20% C; change 
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over 5 min to 70% A, 5% B, and 25% C; and finally change over 5 min to 25% A, 25% 
B, and 50% C. Detection wavelengths were 280 and 325 nm. 
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Appendix	4:	SAS	CODE	
 
data all_groups (label = 'All diet groups')  
zdf_only (label= 'ZDF Animals Only') 
; 
Title2 'Effect of Wheat and Wheat Fractions in ZDF Rats'; 
Input Rat_No Block_No Diet_Group Initial_BW Week_1_BW Week_2_BW 
Week_3_BW MidWeek_4_BW Week_5_BW Total_Weight_Gain Week1_FI Week2_FI 
Week3_FI Average_FI MTT_Time0 Mtt_Time15 MTT_Time30 MTT_Time60 
MTT_Time90 MTT_Time120 
MTT_Time180 BodyWeight_GTT Amount_Gavaged_GTT GTT_Time0 GTT_Time15 
GTT_Time30 GTT_Time60 GTT_Time90 GTT_Time120 GTT_Time180 ITT_Time0 
ITT_Time15 ITT_Time30 ITT_Time60 ITT_Time90 ITT_Time120 
ITT_Time180 Urine_Vol Fecal_DryWeight TissuePCFat_DXA 
Body_Tissue_Weight_DXA Body_Fat_DXA Lean_BW_DXA TissuePCLean_DXA 
BMD_DXA BMC_DXA 
KillDay_BW KillDay_Liver_Weight KillDay_Kidney_Weight Kidney_PC
 KillDay_Epi_fatpad_Weight EpifatPC Retro_perinal_fatpad 
Retro_perinal_fatpadPC Killday_Inguinal_fatpad_weight 
InguinalfatPC Cecum_weight CecumPH Total_LiverLipids_assayed 
Lipids_1g_tissue Liverlipids_whole_liver MTT_AUC GTT_AUC ITT_AUC 
Liver_total_chol_conc_true Liver_total_chol_true 
Liver_free_chol_conc_true Liver_free_chol_true  
fecal_wt_assayed adiponectin_conc pCA FA diOHpropA OH3MepropA 
resistin_sample_ngml fecal_bile_acid TBARS_ug24hr T0_MT_insulin  
T30_MT_insulin T60_MMT_insulin T120_MMT_insulin T180_MMT_insulin 
AUC_MMT_Insulin 
 
; 
 
Label  
Rat_No = 'Rat Number' 
Block_No= 'Block Number' 
Diet_Group= 'Diet Group' 
Initial_BW = 'Initial Body Weight (g)' 
Week_1_BW= 'Week 1 Body Weight (g)'  
Week_2_BW= 'Week 2 Body Weight (g)' 
Week_3_BW = 'Week 3 Body Weight (g)' 
MidWeek_4_BW =' Mid Week 4 Body Weight (g)'   
Week_5_BW ='Week 5 Body weight (g)' 
Total_Weight_Gain = 'Total Weight Gain (g)' 
Week1_FI= ' Food Intake Week 1 (g)'  
Week2_FI = 'Food Intake Week 2 (g)' 
Week3_FI = 'Food Intake Week 3 (g)' 
Average_FI= 'Average Food Intake (g)' 
MTT_Time0  ='Meal Tolerance Test,Blood Glucose at Time 0' 
Mtt_Time15 =' Meal Tolerance Test,Blood Glucose at 15 minutes (mg/dL)' 
MTT_Time30 =' Meal Tolerance Test,Blood Glucose at 30 minutes (mg/dL)' 
MTT_Time60 =' Meal Tolerance Test,Blood Glucose at 60 minutes(mg/dL)' 
MTT_Time90 =' Meal Tolerance Test,Blood Glucose at 90 minutes(mg/dL)' 
MTT_Time120=' Meal Tolerance Test,Blood Glucose at 120 minutes(mg/dL)' 
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MTT_Time180=' Meal Tolerance Test,Blood Glucose at 180 minutes(mg/dL)' 
BodyWeight_GTT= 'Body Weight Measurement for Glucose Tolerance Test 
(g)' 
Amount_Gavaged_GTT=' Amount of Glucose Gavaged During the Glucose 
Tolerance Test (ml)' 
GTT_Time0 = 'Glucose Tolerance Test, Blood Glucose Level at Time 0 
(ml/dL)' 
GTT_Time15 ='Glucose Tolerance Test, Blood Glucose Level at Time 15 
(ml/dL)' 
GTT_Time30='Glucose Tolerance Test, Blood Glucose Level at Time 30 
(ml/dL)' 
GTT_Time60 ='Glucose Tolerance Test, Blood Glucose Level at Time 60 
(ml/dL)' 
GTT_Time90 ='Glucose Tolerance Test, Blood Glucose Level at Time 90 
(ml/dL)' 
GTT_Time120 ='Glucose Tolerance Test, Blood Glucose Level at Time 120 
(ml/dL)' 
GTT_Time180 ='Glucose Tolerance Test, Blood Glucose Level at Time 180 
(ml/dL)' 
ITT_Time0=' Insulin Tolerance Test,Blood Glucose at 0 Minute (ml/dL)' 
ITT_Time15=' Insulin Tolerance Test,Blood Glucose at 15 Minute (ml/dL)' 
ITT_Time30=' Insulin Tolerance Test,Blood Glucose at 30 Minute (ml/dL)' 
ITT_Time60 =' Insulin Tolerance Test,Blood Glucose at 60 Minute 
(ml/dL)' 
ITT_Time90 =' Insulin Tolerance Test,Blood Glucose at 90 Minute 
(ml/dL)' 
ITT_Time120=' Insulin Tolerance Test,Blood Glucose at 120 Minute 
(ml/dL)' 
ITT_Time180=' Insulin Tolerance Test,Blood Glucose at 180 Minute 
(ml/dL)' 
Urine_Vol = 'Urine Volume over 24h Period (ml)' 
Fecal_DryWeight = 'Dry Weight of 48h Fecal Collection (g)' 
TissuePCFat_DXA= '% of Tissue Fat Obtained From DEXA Scanning' 
Body_Tissue_Weight_DXA= 'Body Tissue Weight Obtained by DEXA (g)' 
Body_Fat_DXA ='Total Rat Body Fat Calculated by DEXA (g)' 
Lean_BW_DXA=' Lean Body Weight Calculated by DEXA (g)' 
TissuePCLean_DXA= '% Of lean Tissue of Rat calculated by DEXA (g)' 
BMD_DXA = 'Bone Mineral Density From DEXA, (g/cm2)' 
BMC_DXA= 'Bone Mineral Content (g)' 
KillDay_BW= 'Rat Body Weight At Kill Day (g)' 
KillDay_Liver_Weight= 'Rat Liver Weight at Kill day (g)' 
KillDay_Kidney_Weight= ' Rat Kidney Weight at Kill day  (g)' 
Kidney_PC = 'Kidney weight as a% of body weight' 
KillDay_Epi_fatpad_Weight= 'Kill day Epididymal Fat Pad Weight(g)' 
EpifatPC= 'Epididymal Fat Pad weight as a% of body weight' 
Retro_perinal_fatpad = 'Kill Day Retroperitoneal and Perirenal Fat Pad 
Weight (g)' 
Retro_perinal_fatpadPC= ' Retroperitoneal and Perirenal weight as a% of 
body weight' 
Killday_Inguinal_fatpad_weight= ' Inguinal Fat Pad Weight Kill Day (g)' 
InguinalfatPC = ' Inguinal Fat Pad weight as a% of body weight' 
Cecum_weight = ' Cecum Weight At Kill day (g)' 
CecumPH = ' Cecum pH level at Kill day' 
Total_LiverLipids_assayed='Total Liver Lipids assayed' 
Lipids_1g_tissue= ' Total Liver lipids per Gram of Liver Tissue (ml/g 
L)' 
Liverlipids_whole_liver='Total liver lipids in whole liver (mg/liver)' 
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MTT_AUC='Meal tolerance test AUC' 
GTT_AUC='Glucose tolerance test AUC' 
ITT_AUC='Insulin tolerance test AUC' 
Liver_total_chol_conc_true='Liver total cholesterol conc true (mg/g)'  
Liver_total_chol_true='Liver total cholesterol per liver (mg/liver)' 
Liver_free_chol_conc_true='Liver free cholesterol conc true (mg/g)'  
Liver_free_chol_true='Liver free cholesterol per liver (mg/liver)'  
fecal_wt_assayed='Fecal wt assayed'  
adiponectin_conc='Plasma fasting adiponectin (ug/mL)' 
pCA='urinary total p-caffeic acid (ug/24h)' 
FA='urinary total ferulic acid (ug/24h)' 
diOHpropA='urinary total 3-(3,4-dihydroxy-phenyl)propA (ug/24h)' 
OH3MepropA='urinary total 3-(4-hydroxy-3-methoxy-phenyl)propA (ug/24h)' 
Tot_FA_ref_flour='Total ferulic acid in refined flour (ug/g flour)' 
Tot_FA_WW_flour='Total ferulic acid in whole wheat flour (ug/g flour)' 
Tot_FA_bran='Total ferulic acid in wheat bran (ug/g bran)' 
Tot_FA_germ='Total ferulic acid in wheat germ (ug/g germ)' 
Free_FA_ref_flour='Free ferulic acid in refined flour (ug/g flour)' 
Free_FA_WW_flour='Free ferulic acid in whole wheat flour (ug/g flour)' 
Free_FA_bran='Free ferulic acid in bran (ug/g bran)' 
Free_FA_germ='Free ferulic acid in germ (ug/g germ)' 
resistin_sample_ngml= 'Plasma resistin (ng/ml)'  
fecal_bile_acid = 'Fecal bile acid (mg/24hr)' 
TBARS_ug24hr = 'TBARS (ug/24hr)'  
T0_MT_insulin = 'Insulin response to meal time 0' 
T30_MT_insulin = ' Insulin response to meal time 30' 
T60_MMT_insulin = 'Insulin response to meal time 60' 
T120_MMT_insulin = 'Insulin response to meal time 120' 
T180_MMT_insulin = 'Insulin response to meal time 180' 
AUC_MMT_Insulin = ' Area under the curve for insulin response to meal 
test' 
 
; 
 
; 
 
*Concentration of total ferulic acid in wheat flours and fractions 
(ug/g); 
Tot_FA_ref_flour=67.05; 
Tot_FA_WW_flour=581.50; 
Tot_FA_bran=3031.28; 
Tot_FA_germ=1006.54; 
 
*Concentration of free ferulic acid in wheat flours and 
fractions(ug/g); 
Free_FA_ref_flour=3.04; 
Free_FA_WW_flour=2.42; 
Free_FA_bran=2.48; 
Free_FA_germ=4.25; 
 
*Calculation of the dietary concentration of total ferulic acid for 
each diet (ug/g diet); 
If Diet_Group=3 then Tot_FA_dietconc=153.7*Tot_FA_germ/1000; 
If Diet_Group=4 then Tot_FA_dietconc=650*Tot_FA_WW_flour/1000; 
If Diet_Group=5 then Tot_fa_dietconc=542.7*Tot_FA_ref_flour/1000; 
If Diet_Group=6 then Tot_FA_dietconc=94.2*Tot_FA_bran/1000; 
If Diet_Group=7 then Tot_fa_dietconc=16.2*Tot_FA_germ/1000; 
107 
 
If Diet_Group=1 or Diet_group=2 then Tot_fa_dietconc=.; 
 
*Calculation of the dietary concentration of free ferulic acid for each 
diet (ug/g diet); 
If Diet_Group=3 then Free_FA_dietconc=153.7*Free_FA_germ/1000; 
If Diet_Group=4 then Free_FA_dietconc=650*Free_FA_WW_flour/1000; 
If Diet_Group=5 then Free_FA_dietconc=542.7*Free_FA_ref_flour/1000; 
If Diet_Group=6 then Free_FA_dietconc=94.2*Free_FA_bran/1000; 
If Diet_Group=7 then Free_FA_dietconc=16.2*Free_FA_germ/1000; 
If Diet_Group=1 or Diet_Group=2 then Free_FA_dietconc=.; 
 
*Calculation of the daily total and free ferulic acid intake during 
week 3 (ug); 
Daily_Tot_FA_intake=Week3_FI*Tot_FA_dietconc; 
Daily_free_FA_intake=Week3_FI*Free_FA_dietconc; 
 
*Calculation of estimate of % absorption of ferulic acid from diet, 
based on total and free ferulate in flours & fractions; 
Tot_FA_absorpPC=(FA/Daily_Tot_FA_intake)*100; 
Free_FA_absorpPC=(FA/Daily_free_FA_intake)*100; 
 
*check rat 59 for high value; 
 
output all_groups; 
if Diet_Group = 2 or Diet_Group=3 or Diet_Group =4 or Diet_Group=5 or 
Diet_Group=6 or Diet_Group=7 
then output zdf_only; 
 
Datalines; 
1 1 1 128 149 184 211 224 253 125.0  13.35
 14.80 17.70 15.28  98 143 148 165 171 142 157 
 190 0.19 104 127 140 98 104 95 92  103
 35 . . . . .  1.25  2.98 
 15.5 218 34 184 84.404 0.157 5.312  253
 6.6115 1.5605 0.617 0.979 0.387 1.865 0.737 2.003 0.792
 0.4053 7.02 74.41 68.20 450.89 27390 18930 . 6.752
 44.64 2.082 13.765 100.13 34.49 28.51 12.20 67.11 56.52
 23.08313842 3.5054 2.3282 0.422 0.4505 1.5517
 0.5505 2.055 184.3515 
2 1 1 128 151 195 224 234 252 124.5  15.30
 15.65 17.15 15.65  81 133 178 146 147 187 152 
 200 0.2 90 147 108 75 90 87 70  92
 47 35 34 30 39 75  1.35  2.95 
 17.7 232 41 191 82.328 0.146 5.600  252
 8.9562 1.8718 0.743 0.812 0.322 1.077 0.428 1.579 0.627
 0.4126 6.48 67.05 63.74 570.83 28373 16275 8108 6.678
 59.81 2.107 18.872 101.55 33.52 32.45 13.29 84.27 84.88
 21.5309377 3.2318 2.8651 0.5 0.532 0.7904 
 0.6471 35.316 
3 1 1 111 137 171 195 206 223 112.4  15.25
 13.75 14.10 14.37  117 134 169 148 177 178 164 
 179 0.179 112 134 110 102 103 98 100  97
 53 39 42 40 59 86  0.8  2.63 
 21.4 204 44 160 78.431 0.139 4.839  223 7.456
 1.526 0.684 0.940 0.421 0.938 0.420 1.252 0.561 0.3349 7.1
 46.29 52.16 388.89 29370 18885 10095 5.011 37.36 1.963
 14.634 101.43 35.94 22.76 9.77 64.32 58.74 20.91431001
108 
 
 2.815 1.9379 0.2857 0.3367 1.4871 0.6087
 0.3368 127.932 
4 1 1 133 159 204 225 253 255 122.3  26.60
 16.95 20.50 21.35  91 125 152 160 176 154 156 
 201 0.2 111 140 113 97 103 99 97  120
 46 49 36 46 89 77  1.62  3.27 
 19.5 242 47 195 80.579 0.145 5.906  255
 7.6913 1.9174 0.752 1.065 0.418 1.071 0.420 1.449 0.568
 0.4145 6.77 87.36 73.61 566.15 27668 18840 11468 6.984
 53.71 2.068 15.904 101.06 31.57 35.18 14.08 74.34 87.56
 16.87433553 3.293 3.1008 0.4 0.5116 0.887 0.3965
 0.4548 98.697 
5 1 1 131 159 199 212 228 242 111.3  16.85
 18.00 17.45 17.43  97 122 178 134 151 147 156 
 185 0.18 116 138 119 102 100 94 93  85
 51 22 . . . .  1.8  3.37 
 17.2 229 39 189 82.533 0.148 5.426  242 7.411
 1.7684 0.731 0.981 0.405 1.273 0.526 1.445 0.597 0.3827
 6.92 86.56 82.98 614.93 26408 18698 1568 9.193 68.13 2.000
 14.823 99.68 29.48 38.18 15.04 79.39 71.02 18.17137997
 3.2552 2.9015 0.3333 0.4 0.5716 0.4072
 0.3154 76.6155 
6 2 3 192 226 280 315 341 360 168.0  21.25
 22.75 23.20 22.40  152 176 177 184 166 192 196 
 282 0.282 136 232 224 189 144 144 147  143
 140 87 87 103 107 119  8.5  5.18 
 50.4 333 168 165 49.550 0.149 7.368  360
 15.6131 2.1918 0.609 3.829 1.064 5.518 1.533 15.176
 4.215 0.4841 6.7 120.55 97.28 1518.85 32783 30420
 19215 7.974 124.50 1.668 26.037 101.36 25.70
 174.50 142.57 258.71 365.50 24.1936101
 3.8644 12.0962 2.3462 4.9593 3.3996
 2.4483 1.6447 533.193 
7 2 3 184 221 275 310 334 352 168.0  24.97
 24.80 25.15 24.98  127 165 146 116 155 147 146 
 278 0.278 111 204 211 183 140 137 139  137
 113 76 72 94 108 108  13.4  4.74 
 63.1 324 205 120 37.037 0.160 10.707  352
 12.1462 1.9533 0.555 4.288 1.218 5.779 1.642 15.594
 4.430 0.3458 6.55 83.28 90.13 1094.74 25838 28665 17513
 7.135 86.66 1.879 22.823 100.82 38.33 152.62
 156.77 246.01 347.19 22.87354123 3.7473 6.296
 1.9257 3.6101 1.9444 0.5053 3.3504
 355.5165 
8 2 3 182 216 265 296 324 340 158.0  21.25
 23.10 20.65 21.67  114 197 141 143 163 172 148 
 271 0.271 161 240 213 207 145 154 158  135
 118 78 90 115 148 128  8.4  4.32 
 47.7 313 150 164 52.396 0.159 7.202  340
 13.7201 2.1124 0.621 3.791 1.115 5.295 1.557 12.720
 3.741 0.3995 6.6 97.32 95.51 1310.47 28343 31830 21188
 5.965 81.84 1.871 25.676 100.95 31.84 134.20
 129.21 245.65 298.35 20.67342644 4.2732
 10.1376 1.2373 1.3277 1.3603 0.8977
 1.5704 220.578 
9 2 3 205 243 293 318 340 355 150.0  22.10
 23.30 24.70 23.37  117 150 134 152 164 163 181 
109 
 
 297 0.297 158 224 223 208 202 207 194  187
 143 96 91 112 165 155  17  5.59 
 52.6 337 177 160 47.478 0.155 7.538  355
 18.1189 2.4789 0.698 4.090 1.152 5.734 1.615 12.848
 3.619 0.4498 6.85 166.07 126.03 2283.53 28388
 36998 23873 8.957 162.29 1.714 31.061 101.18 26.53
 191.40 141.67 226.41 353.55 15.50793954
 4.2904 12.7235 5.402 10.0446 5.917 9.4858
 5.4591 1381.554 
10 2 3 193 235 282 315 342 353 160.0  24.10
 20.75 27.25 24.03  124 182 173 197 183 174 184 
 294 0.294 113 165 294 158 160 126 140  138
 101 74 90 111 129 127  23.5  5.58 
 49.8 338 168 170 50.296 0.161 7.520  353
 18.1068 2.6904 0.762 4.409 1.249 6.020 1.705 11.597
 3.285 0.4305 6.73 158.62 115.27 2087.13 32303
 29348 19860 8.518 154.23 1.643 29.755 101.43 21.66
 197.65 127.90 161.71 221.74 19.90816912
 5.0544 12.092 3.9801 2.0971 3.8738
 4.5053 . 432.0945 
11 1 2 175 216 269 287 310 337 161.8  24.50
 22.75 15.35 20.87  164 235 229 159 204 219 200 
 268 0.26 147 202 191 182 149 146 134  189
 140 81 82 124 156 158  4.8  4.95 
 51.7 307 159 149 48.534 0.161 6.720  337
 16.5345 1.7864 0.530 3.639 1.080 4.503 1.336 9.832 2.918
 0.3356 7.01 245.63 216.97 3587.47 36653 28950
 23280 12.156 200.99 1.607 26.573 100.62 41.93
 47.76 12.84 185.52 182.65 22.21135445 3.5814
 6.1267 0.4536 1.4617 7.7185 0.3336
 5.1693 573.0825 
12 1 2 160 190 245 275 291 318 158.3  20.75
 22.05 . 31.58  108 149 155 136 273 161 196 
 247 0.24 137 194 221 172 156 153 139  137
 112 97 77 130 137 156  5.4  4.58 
 63.2 284 180 105 36.972 0.157 9.072  318
 12.6854 1.678 0.528 3.645 1.146 4.398 1.383 8.270 2.601
 0.3391 7.31 125.09 107.74 1366.77 31928 29805
 21945 9.168 116.30 1.792 22.728 101.36 41.22 43.68
 11.52 123.72 182.52 20.08505209 2.6786 6.778 1.482
 2.237 2.668 0.8015 0.7082 278.736 
13 1 2 155 184 240 263 282 302 146.8  18.90
 21.20 20.00 20.03  117 171 113 156 194 199 182 
 235 0.23 124 230 219 183 183 179 141  124
 133 73 77 118 133 142  3.8  4.15 
 62.3 275 172 104 37.818 0.155 9.031  302
 11.553 1.6504 0.546 3.373 1.117 4.339 1.437 10.492
 3.474 0.3192 6.9 137.81 111.03 1282.73 30900
 32573 20663 2.217 25.61 1.754 20.260 101.33 39.63 48.05
 13.24 130.16 157.15 22.38145864 2.0875 6.8051
 3.445 5.4643 1.4537 1.6598 1.212 416.9685 
14 1 2 169 201 256 284 308 330 161.5  20.85
 21.95 20.40 21.07  139 196 124 157 155 195 210 
 263 0.26 160 248 233 215 177 151 121  145
 131 60 75 100 145 129  5  4.19 
 53.2 300 160 140 46.667 0.165 7.380  330
 14.1342 1.7737 0.537 4.072 1.234 4.464 1.353 9.577 2.902
110 
 
 0.2552 6.97 163.18 138.88 1962.91 31208 32348
 20048 11.587 163.78 1.833 25.903 101.25 48.24
 64.31 19.97 164.99 183.41 23.18945354 2.8865
 5.7858 1.388 5.0043 11.789 2.2418 6.9265
 1043.757 
15 1 2 175 207 162 290 317 352 177.5  22.75
 23.35 19.95 22.02  139 193 152 152 155 166 207 
 270 0.27 187 247 233 210 192 173 138  140
 130 59 88 113 138 132  4.1  4.74 
 51.8 312 162 150 48.077 0.157 6.600  352
 15.642 1.994 0.566 4.227 1.201 5.315 1.510 13.647 3.877
 0.3435 6.6 199.9 161.30 2523.07 30248 34335 20528
 11.760 183.95 2.024 31.655 101.30 39.04
 509.51 5.88 149.37 165.67 20.63789071 3.382
 4.6863 4.2735 29.801 13.9682 . 9.0356
 1167.6555 
16 2 2 178 209 267 288 315 327 149.0  21.95
 21.60 21.15 21.57  172 250 157 163 183 192 188 
 265 0.265 152 195 201 185 160 164 165  137
 137 74 72 137 125 130  8.2  4.13 
 54.6 308 168 140 45.455 0.147 6.984  327
 15.134 1.8494 0.566 3.653 1.117 4.873 1.490 15.191
 4.645 0.3373 6.93 203.35 158.84 2403.92 33233
 31268 20543 14.427 218.34 1.814 27.458 101.20
 31.19 48.92 15.09 155.34 136.08 23.52400995 3.1642
 7.8335 5.332 10.875 3.2972 4.8635 5.5578
 1013.148 
17 2 2 186 218 284 297 319 335 149.0  20.75
 20.60 22.55 21.30  168 218 190 229 221 216 200 
 272 0.272 144 277 254 224 186 162 165  160
 152 97 79 130 153 162  58.5  4.42 
 54.5 314 171 143 45.541 0.156 7.240  335
 15.8483 1.9274 0.575 3.859 1.152 5.122 1.529 14.068
 4.199 0.3804 6.73 149.47 136.61 2165.11 38025
 35490 23678 12.882 204.16 1.819 28.828 101.16
 25.70 35.64 0.04 119.30 118.37 15.62272814 3.0837
 4.9257 4.7369 2.4158 15.1639 6.1575
 2.9553 1284.012 
18 2 2 193 224 254 267 314 342 149.0  21.95
 23.25 . 22.60  140 194 130 165 148 157 176 
 262 0.262 142 225 196 152 108 128 121  176
 159 129 130 158 164 157  6.9  4.94 
 52.4 311 163 148 47.588 0.155 7.108  342
 15.9663 2.0456 0.598 3.820 1.117 5.505 1.610 11.814
 3.454 0.3607 6.65 256.95 220.60 3522.10 28620
 26040 27338 13.237 211.35 1.762 28.139 101.08
 27.80 68.97 25.55 139.17 184.29 16.56016836 3.6798
 6.3764 3.4606 4.6655 3.791 12.2871 0.9113
 1127.034 
19 2 2 168 205 285 285 312 331 163.0  24.20
 21.80 21.40 22.47  105 243 196 164 207 186 168 
 265 0.265 158 252 258 235 220 215 211  152
 137 101 82 127 165 167  6.8  3.65 
 54.6 306 167 139 45.425 0.153 6.837  331
 14.5412 1.8183 0.549 3.704 1.119 5.069 1.532 10.589
 3.199 0.3657 6.52 267.63 209.53 3046.79 33383
 40425 24173 18.028 262.15 2.272 33.033 101.29
111 
 
 36.38 46.38 35.06 151.91 200.60 19.35335757 2.3507
 4.7006 3.7102 5.7922 2.9553 2.4484
 5.5296 675.1995 
20 2 2 196 233 284 317 346 365 169.0  24.50
 23.05 25.15 24.23  118 227 163 202 201 201 221 
 297 0.297 129 229 209 187 161 168 168  136
 122 74 108 123 152 152  20.05  5.16 
 53.2 340 181 159 46.765 0.159 7.791  365
 18.5417 4.1639 1.141 2.231 0.611 5.445 1.492 11.531
 3.159 0.3355 6.58 238.45 214.32 3973.78 35723
 32145 . 17.001 315.22 2.074 38.463 101.93
 25.56 34.75 41.02 150.77 153.02 21.38128946 2.2515
 . 4.3413 9.5966 7.6407 . 3.1633
 467.628 
21 1 4 164 194 245 273 285 298 134.3  20.25
 21.95 21.10 21.10  144 200 177 208 202 218 211 
 247 0.24 113 213 194 153 118 110 116  120
 131 91 85 99 114 123  16  3.59 
 56.2 280 158 123 43.929 0.153 5.981  298
 13.8018 2.092 0.702 3.853 1.293 4.352 1.461 8.349 2.802
 0.4743 6.17 120.08 118.26 1632.18 36503 24968
 19253 11.608 160.21 1.952 26.939 100.48 29.33
 15.92 227.05 348.37 198.17 16.00255156 6.5087
 9.7504 1.218 0.864 3.2061 1.0269 2.5994
 328.0605 
22 1 4 157 185 240 268 286 306 149.3  19.00
 21.30 24.20 21.50  103 174 184 232 197 176 188 
 245 0.24 116 187 157 132 167 108 .  117
 72 67 73 109 107 125  8  3.71 
 50.4 283 142 140 49.470 0.144 5.743  306
 12.545 1.8591 0.608 3.231 1.056 3.209 1.049 7.698 2.516
 0.5232 6.01 109.35 94.67 1187.60 33953 17798 17490
 6.879 86.29 1.590 19.944 101.39 38.71 11.37 196.59
 497.97 154.36 20.85052094 7.0962 7.4624
 0.4969 0.7758 1.2261 0.7609 0.8155
 156.021 
23 1 4 172 201 244 273 283 306 133.8  20.45
 22.25 23.80 21.35  99 146 132 114 170 125 167 
 245 0.24 122 220 289 190 219 139 152  117
 100 64 95 112 124 121  29.5  3.79 
 54.8 283 155 128 45.230 0.153 5.949  306
 15.048 2.0146 0.658 3.788 1.238 4.700 1.536 7.829 2.558
 0.5818 6.17 137.38 132.47 1993.34 25058 33803
 19238 11.481 172.77 1.634 24.590 100.19 34.49
 22.57 279.28 339.44 237.08 15.21581969 6.9954
 12.5215 4.604 10.6724 11.7723 1.4209 3.9063
 1121.4285 
24 1 4 182 213 265 293 316 336 153.6  20.40
 25.85 22.00 23.13  121 136 132 119 130 143 170 
 275 0.27 115 187 155 118 105 108 131  113
 90 51 42 83 92 132  21  3.33 
 52.7 312 164 147 47.115 0.141 6.756  336
 15.0468 2.237 0.666 3.662 1.090 4.733 1.409 8.088 2.407
 0.5536 5.66 140.84 112.90 1698.75 24923 22635
 15195 11.754 176.86 1.857 27.938 101.10 36.77
 25.27 375.08 450.24 292.08 22.19009143 6.7331
112 
 
 11.0995 0.8121 2.388 6.6264 2.1184 1
 539.1135 
25 1 4 187 209 253 283 311 325 138.1  23.45
 24.75 23.90 24.03  156 131 116 109 124 137 165 
 260 0.26 134 215 198 164 157 159 132  120
 79 67 69 127 132 129  18.5  3.78 
 52.3 311 163 148 47.588 0.152 6.964  325
 17.0682 2.225 0.685 4.117 1.267 4.953 1.524 11.950 3.677
 0.5362 5.94 114.54 120.68 2059.84 23850 29430
 19283 9.883 168.69 1.802 30.752 101.39 23.02 14.37
 275.68 485.33 263.84 14.25898363 7.4601
 11.0121 2.1935 8.4388 10.1971 1.4516
 1.8893 888.711 
26 2 4 195 230 282 325 359 372 177.0  20.70
 23.95 25.95 23.53  140 233 187 232 216 248 206 
 293 0.293 123 223 210 161 110 147 148  121
 118 74 90 111 104 132  15  4 
 49.6 351 174 177 50.427 0.156 7.989  372
 17.2865 2.3062 0.620 3.606 0.969 5.720 1.538 11.064
 2.974 0.6004 6.66 133.48 130.10 2248.93 39533
 28178 19013 12.703 219.59 1.623 28.053 101.11
 27.15 46.23 470.50 522.15 393.47 19.56380333
 3.3955 12.2089 3.5634 5.0598 12.352
 3.2939 1.5913 1006.458 
27 2 4 160 195 255 295 325 340 180.0  20.90
 23.60 20.25 21.58  121 183 131 172 196 178 193 
 262 0.262 138 198 204 180 133 149 128  135
 93 67 80 108 118 116  8.85  3.72 
 50.1 320 160 160 50.000 0.140 6.442  340
 14.7619 2.3704 0.697 3.974 1.169 5.107 1.502 13.127
 3.861 0.5631 6.68 96.03 100.50 1483.61 31440 28530
 18345 8.785 129.69 1.723 25.439 100.33 29.60 22.78
 256.19 549.23 198.27 21.62999809 2.9936
 10.3587 2.0265 1.8558 4.1965 0.7505
 2.2724 388.116 
28 2 4 226 252 295 332 359 364 138.0  23.40
 23.00 24.65 23.68  120 178 117 133 130 162 203 
 303 0.303 121 208 272 148 126 135 156  119
 108 83 73 100 107 124  27  4.18 
 50.7 354 179 174 49.153 0.153 7.618  364
 18.1672 2.2281 0.612 4.229 1.162 6.040 1.659 14.293
 3.927 0.571 6.76 137.26 115.64 2100.78 27473 29123
 18105 12.799 232.53 1.791 32.545 101.19 23.93
 21.40 361.30 521.40 357.41 20.04208915 5.9583
 16.2505 2.6894 . 16.252 5.7815 3.0028
 924.534 
29 2 4 188 223 270 305 330 353 165.0  20.40
 21.55 26.00 22.65  113 171 130 201 226 183 188 
 285 0.285 119 213 224 161 145 149 163  124
 113 71 66 105 136 150  11.5  4.07 
 51.5 326 168 158 48.466 0.158 7.407  353
 15.6103 2.3973 0.679 3.752 1.063 4.911 1.391 11.123
 3.151 0.4662 6.43 106.45 103.73 1619.29 33023
 29903 19973 8.392 130.99 1.589 24.798 100.66 31.51
 50.10 434.17 658.71 364.94 24.09795294 4.6911
 10.7469 2.0107 3.0558 6.2158 3.761 5.6988
 798.1695 
113 
 
30 2 4 196 232 276 292 306 314 118.0  21.50
 25.30 27.65 24.82  144 186 140 154 153 167 178 
 275 0.275 140 201 224 181 153 158 161  170
 156 81 98 119 155 205  55.5  3.99 
 49.2 296 146 150 50.676 0.157 7.055  314
 18.3242 2.4717 0.787 3.553 1.131 4.931 1.570 11.280
 3.592 0.3816 6.2 130.51 131.95 2417.85 29085
 31065 25073 14.357 263.09 1.446 26.505 101.24
 17.77 25.05 377.65 484.50 332.11 14.93399656
 4.0293 20.4231 5.904 16.9536 5.4591 6.3788
 6.8262 1430.3415 
31 1 5 136 170 224 258 275 300 164.1  20.20
 21.40 22.70 20.80  151 197 190 196 219 201 206 
 231 0.23 125 199 186 171 151 133 132  139
 108 68 97 117 121 116  9.8  3.88 
 50.7 271 138 134 49.446 0.160 6.374  300
 13.5883 1.9948 0.665 3.263 1.088 3.750 1.250 7.317 2.439
 0.4126 6.88 117.1 98.14 1333.55 36038 27713 19538 8.841
 120.13 1.696 23.049 100.59 40.81 39.97 74.50
 198.74 202.69 23.4233468 2.9337 8.2698 2.111
 10.3992 4.0298 1.2786 3.237 698.808 
32 1 5 159 187 243 277 291 319 160.0  21.25
 22.05 23.40 22.23  117 131 155 200 170 212 201 
 247 0.24 192 238 252 196 160 137 146  125
 116 81 111 126 140 121  6.4  3.63 
 53.7 290 156 134 46.207 0.146 6.092  319
 12.544 1.8376 0.576 3.530 1.106 5.293 1.659 9.063 2.841
 0.465 6.8 107.19 94.42 1184.35 33000 31905 21540 7.647
 95.93 1.669 20.939 100.72 54.38 21.58 38.02 143.54
 224.57 21.8924091 3.3182 4.8057 0.5627
 2.9056 3.2594 0.7195 1.2025 321.5265 
33 1 5 183 215 265 290 303 318 135.0  20.45
 26.05 23.60 23.37  152 202 155 179 153 182 219 
 260 0.26 133 233 189 187 138 125 114  93
 82 52 47 79 112 128  28.5  5.67 
 51.9 300 155 144 48.000 0.159 6.848  318
 17.0641 2.3688 0.745 3.726 1.172 5.064 1.592 9.179 2.886
 0.474 6.57 151.53 161.03 2747.85 32378 27540 15758
 17.816 304.01 2.604 44.434 101.52 23.82 45.72
 64.64 199.14 227.99 12.04762917 4.3861 13.8252
 5.0982 9.8751 1.1707 1.0766 3.0306
 580.9215 
34 1 5 176 215 273 307 330 353 176.7  24.00
 26.50 25.25 25.25  132 174 112 133 160 174 205 
 282 0.282 154 216 206 176 148 153 138  117
 103 41 71 106 123 153  9.4  4.33 
 63.3 322 204 118 36.646 0.159 10.681  353
 16.2914 2.1317 0.604 3.867 1.095 5.447 1.543 10.657
 3.019 0.4131 6.8 108.62 112.01 1824.87 28890
 29775 18780 9.405 153.22 1.679 27.357 101.52 37.89
 31.66 46.23 185.74 223.08 17.78864555 3.6029
 9.6327 3.6044 6.793 4.479 1.4633 4.4792
 681.585 
35 1 5 192 219 261 289 305 335 142.7  28.65
 26.05 25.05 26.58  144 196 153 175 147 159 189 
 265 0.26 116 171 176 145 145 132 131  120
 96 62 71 100 113 121  7.8  4.06 
114 
 
 49.6 300 149 151 50.333 0.160 7.120  335
 14.9641 2.1642 0.646 3.387 1.011 5.536 1.653 11.056
 3.300 0.4848 6.89 117.87 122.15 1827.79 29948
 25965 17580 11.747 175.78 1.928 28.852 101.15
 40.01 28.56 47.15 204.25 173.55 20.04252605 3.9073
 7.8512 2.4203 12.1587 2.3733 4.3324
 5.3642 928.734 
36 2 5 191 226 274 309 334 348 157.0  21.33
 23.75 22.25 22.44  131 194 115 125 167 164 161 
 282 0.282 133 212 196 169 156 138 140  132
 109 91 89 104 115 117  5.3  4.19 
 54.3 325 176 149 45.846 0.160 7.687  348
 13.7559 2.0398 0.586 3.991 1.147 4.376 1.257 14.398
 4.137 0.4319 7.08 115.01 95.92 1319.49 27450 28748
 19148 10.357 142.47 1.800 24.762 101.32 35.41
 35.81 34.95 202.40 225.35 18.26286589 4.5971
 6.5065 4.22 5.3984 3.1272 . 4.8345
 272.16 
37 2 5 186 217 266 295 320 337 151.0  20.95
 20.30 24.30 21.85  146 175 116 142 166 195 211 
 265 0.265 125 195 191 158 120 122 137  140
 107 71 86 107 118 129  15  3.83 
 49.3 316 156 160 50.633 0.163 7.658  337
 14.6512 2.2483 0.667 3.605 1.070 4.960 1.472 11.403
 3.384 0.5094 7.03 110.34 111.16 1628.67 30675
 26100 19223 11.062 162.08 1.757 25.736 100.27
 38.00 37.68 62.11 221.68 214.77 22.01262675 4.1836
 9.8233 4.9711 7.4978 8.0948 5.0681
 2.7453 1050.2115 
38 2 5 175 207 261 289 313 330 155.0  21.05
 23.20 22.95 22.40  130 191 126 180 230 199 156 
 260 0.26 138 245 219 178 163 134 158  124
 120 83 82 124 154 136  5  3.9 
 55.7 306 171 136 44.444 0.147 6.674  330
 13.1756 1.9671 0.596 3.372 1.022 4.039 1.224 12.260
 3.715 0.437 7.06 105.42 89.12 1174.21 32610 30638 21788
 7.707 101.54 1.741 22.933 101.31 36.85 36.81 49.59
 188.18 250.47 18.26286589 3.7731 6.8763
 6.6442 5.0404 10.255 9.7871 2.2435
 1366.881 
39 2 5 189 220 261 293 311 329 140.0  21.40
 22.60 25.60 23.20  123 243 169 199 243 193 204 
 270 0.27 110 169 155 138 132 135 138  100
 98 69 75 121 152 131  15  4.36 
 54.1 302 163 139 46.026 0.162 6.886  329
 14.7276 1.9718 0.599 3.671 1.116 4.966 1.510 12.595
 3.828 0.3584 6.99 157.83 129.85 1912.35 36435
 25163 20423 13.284 195.64 1.882 27.712 101.41
 29.10 58.14 34.73 256.66 468.51 16.15840826 3.9256
 7.3129 1.978 16.0877 6.1786 10.6476 2.6485
 1508.649 
40 2 5 196 234 276 308 333 346 150.0  23.40
 21.65 25.02 23.36  135 193 156 170 159 195 210 
 291 0.291 101 169 185 189 147 143 147  123
 118 85 85 126 139 171  7.5  3.56 
 53.8 329 177 152 46.201 0.154 7.632  346
 14.1223 2.1216 0.613 3.752 1.084 5.352 1.547 11.709
115 
 
 3.384 0.4023 6.93 155.66 141.38 1996.62 32363
 28380 22320 12.636 178.45 1.869 26.393 100.97
 37.68 41.83 34.95 197.37 240.31 16.63669409 3.6839
 8.7708 1.6903 13.2606 4.8212 6.4298
 6.3969 1217.8215 
41 1 6 187 228 282 316 331 342 155.2  23.70
 24.95 27.25 24.33  159 248 173 178 221 201 175 
 286 0.28 134 181 170 166 153 135 125  162
 125 85 92 99 133 164  22  7.1 
 61.8 327 202 125 38.226 0.162 10.878  342
 18.505 2.4252 0.709 3.954 1.156 5.257 1.537 11.025
 3.224 0.3454 6.7 134.63 110.82 2050.64 28860
 26940 21638 8.500 157.29 1.687 31.218 101.04 22.69
 61.08 299.24 336.67 357.83 15.74739528 7.149
 12.3396 0.895 5.482 4.1319 3.2184 2.462 630.7845 
42 1 6 153 190 244 279 298 323 169.7  21.65
 23.00 24.20 22.95  125 162 142 161 221 193 177 
 250 0.25 160 225 247 184 158 146 144  121
 118 64 84 100 113 125  6  4.29 
 50 291 145 146 50.172 0.160 7.044  323
 13.6405 2.013 0.623 3.741 1.158 4.186 1.296 8.347 2.584
 0.3685 6.48 94.63 72.76 992.47 32018 31283 18473 5.372
 73.28 1.581 21.562 101.90 40.95 30.69 275.79
 355.85 331.70 22.19009143 4.0514 8.1556
 0.5255 7.0734 0.6456 0.8264 0.9456
 327.0885 
43 1 6 186 221 278 310 332 333 147.2  22.55
 29.60 28.95 27.03  149 209 140 150 197 209 181 
 280 0.28 115 179 185 150 130 124 120  114
 108 65 56 69 108 120  58  6.08 
 51.3 329 169 160 48.632 0.155 6.853  333
 18.3465 2.4173 0.726 4.149 1.246 5.761 1.730 8.770 2.634
 0.5175 7.12 153.35 142.68 2617.64 32648 25290
 16148 13.016 238.80 2.009 36.858 101.49 25.61
 67.81 490.12 398.06 422.99 13.74867106 6.8462
 . 4.9812 10.8575 1.5396 5.8578 2.4906
 895.911 
44 1 6 172 206 163 303 325 345 172.9  24.15
 26.45 23.20 24.60  114 173 131 151 160 189 196 
 279 0.279 159 228 201 178 152 149 144  124
 101 64 60 92 124 146  13  5.57 
 64.4 313 202 111 35.463 0.158 9.534  345
 14.4325 1.9644 0.569 4.362 1.264 6.075 1.761 9.978 2.892
 0.3661 7.36 108.87 95.57 1379.27 30113 30060 18405
 7.827 112.97 1.888 27.243 100.75 32.72 46.03
 432.64 421.69 505.77 16.83180948 6.2804
 10.4578 2.55 6.2509 4.3516 3.3982 4.1559
 750.168 
45 1 6 166 192 235 264 296 322 156.1  23.85
 24.20 23.25 23.77  150 198 142 191 201 205 198 
 240 0.24 151 213 212 143 157 143 136  130
 117 67 71 105 116 127  6.4  5 
 46.1 291 134 157 53.952 0.166 7.485  322
 14.225 2.0515 0.637 2.986 0.927 4.501 1.398 8.717 2.707
 0.3766 6.55 122.2 101.91 1449.67 34215 28613 18548
 8.707 123.86 1.585 22.542 101.27 39.04 68.92
 234.53 446.67 257.87 24.91175845 3.7326
116 
 
 7.4446 0.4194 2.0813 1.1843 1.1775
 2.6997 273.6645 
46 2 6 192 231 283 320 352 368 176.0  23.15
 23.85 25.75 24.25  157 234 175 177 181 203 176 
 292 0.292 148 244 230 192 159 128 154  143
 144 102 80 118 121 128  8.2  4.99 
 51 347 177 170 48.991 0.156 7.545  368
 14.3895 2.1335 0.580 4.194 1.140 5.174 1.406 12.032
 3.270 0.4487 6.76 107.8 104.91 1509.67 33780 30855
 20753 8.457 121.69 1.700 24.469 101.32 28.45 45.44
 250.29 500.43 306.44 20.04208915 5.0499
 9.7173 4.0479 12.1379 12.1243 4.0373
 4.8206 1357.305 
47 2 6 152 182 230 266 290 302 150.0  17.75
 20.60 22.30 20.22  108 214 157 146 162 168 175 
 235 0.235 153 276 245 187 167 165 146  143
 104 71 89 117 122 117  6.8  4.57 
 54.6 280 153 127 45.357 0.159 6.896  302
 10.7227 1.6363 0.542 3.544 1.174 4.381 1.451 12.524
 4.147 0.3387 6.93 92.62 87.97 943.33 29603 33225 19410
 6.035 64.72 1.672 17.933 101.05 45.44 39.66 251.41
 584.49 327.00 19.64032906 4.7678 7.2665 1.311
 3.1485 2.2365 2.24 1.357 389.8725 
48 2 6 194 224 267 297 318 334 140.0  23.10
 20.80 24.50 22.80  137 228 201 180 202 199 176 
 278 0.278 120 184 192 223 200 165 162  147
 121 63 87 122 131 171  6.8  4.34 
 57.9 312 181 131 41.987 0.149 6.895  334
 12.8906 2.0541 0.615 4.018 1.203 5.495 1.645 13.449
 4.027 0.3553 6.75 91.34 100.16 1291.18 34665 32955
 21630 8.992 115.91 1.799 23.190 100.79 29.42 56.18
 265.94 624.32 390.88 10.70594988 3.9526
 6.8495 0.8703 9.8262 2.3488 7.191 4.1102
 968.3025 
49 2 6 196 230 276 305 328 348 152.0  21.75
 21.00 25.00 22.58  164 287 212 223 250 185 224 
 288 0.288 142 168 167 140 122 126 122  128
 108 54 78 100 137 120  8.6  5.01 
 53.5 321 172 149 46.417 0.151 7.116  348
 13.6027 2.1557 0.619 3.692 1.061 4.785 1.375 9.975 2.866
 0.3165 6.9 99.2 104.45 1420.86 39540 24533 18900
 10.491 142.71 1.771 24.095 100.39 29.42 56.14
 266.33 539.50 288.68 19.18117467 4.5533
 8.5464 3.2585 4.7735 9.3786 12.5523
 2.5875 1444.8825 
50 2 6 198 238 269 310 340 354 156.0  25.00
 13.45 19.40 19.28  178 251 195 267 242 246 205 
 294 0.294 143 193 236 249 226 190 193  149
 153 94 94 130 170 175  6.4  4.54 
 63.2 326 206 120 36.810 0.167 11.429  354
 14.5118 1.9674 0.556 4.279 1.209 5.435 1.535 14.208
 4.014 0.3054 6.75 86.92 86.60 1256.72 41978 37868 25148
 7.732 112.20 1.711 24.836 101.09 28.95 30.23
 184.77 484.71 221.05 20.36732351 3.8393 8.662
 3.4651 5.7276 7.6407 7.3589 4.3142
 1138.596 
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51 1 7 159 195 242 272 288 314 155.2  23.60
 23.00 21.58 22.73  127 185 190 180 280 206 198 
 249 0.24 128 194 177 167 157 131 129  149
 112 68 78 109 132 120  5.7  5.18 
 56.3 289 163 126 43.599 0.150 6.046  314
 14.4887 2.2266 0.709 3.444 1.097 3.737 1.190 10.055
 3.202 0.3494 6.94 148.36 125.40 1816.87 37013
 27338 19478 9.474 137.27 2.111 30.585 101.74 36.59
 41.40 17.50 97.24 143.84 20.91431001 4.0012 5.8123
 4.9067 3.5123 1.2577 0.677 3.4654 380.148 
52 1 7 142 176 234 270 290 324 181.9  21.65
 22.40 23.05 22.37  129 174 173 156 185 178 206 
 241 0.241 153 227 199 173 147 134 130  128
 101 68 101 131 142 115  7.4  4.48 
 66.7 281 187 94 33.452 0.158 9.841  324
 13.2501 1.8464 0.570 3.571 1.102 4.906 1.514 10.788
 3.329 0.3071 6.66 107.09 101.95 1350.87 31890
 28560 20805 8.326 110.32 1.734 22.971 100.56 45.65
 103.87 35.11 199.88 303.49 18.25643206 3.2892
 8.2189 0.6894 10.0089 0.814 2.8873 3.1557
 615.147 
53 1 7 192 228 283 317 346 366 174.4  24.70
 25.95 24.65 25.10  144 181 215 177 207 180 178 
 291 0.29 119 188 183 148 134 127 127  128
 86 75 62 81 131 115  10.25  5.35 
 64.1 334 214 120 35.928 0.154 10.359  366
 16.6927 2.1533 0.588 4.190 1.145 5.353 1.463 10.318
 2.819 0.4032 6.49 155.82 155.46 2595.09 33593
 25815 17573 10.632 177.48 1.911 31.902 101.18
 46.47 53.83 17.88 138.72 196.95 23.91239634 3.077
 7.1268 2.9712 6.4573 2.9727 5.0512
 5.8171 849.6435 
54 1 7 180 217 270 293 320 334 154.2  21.35
 24.45 20.60 22.13  113 126 126 170 176 201 217 
 272 0.27 158 224 195 177 157 131 133  134
 85 68 81 107 131 140  5.6  4.33 
 52.7 315 166 149 47.302 0.156 7.281  334
 11.6951 1.9605 0.587 4.191 1.255 5.551 1.662 13.460
 4.030 0.4183 6.9 101.95 99.10 1158.94 31508 28838
 19545 7.834 91.62 1.789 20.919 100.68 47.27 50.21 23.40
 134.35 213.32 18.41591735 3.8665 6.8819
 3.2284 5.4085 5.082 6.9092 4.8576 999.651 
55 1 7 173 198 241 273 301 319 145.9  21.25
 22.40 22.75 22.13  157 218 184 174 222 208 196 
 250 0.25 139 224 140 152 131 133 130  138
 105 61 82 116 114 133  5  4.49 
 50.5 294 148 146 49.660 0.176 7.645  319
 12.1531 1.9277 0.604 3.653 1.145 4.783 1.499 9.992 3.132
 0.3766 6.37 81.44 88.50 1075.58 35708 25928 19043 8.434
 102.50 1.979 24.051 101.50 26.35 49.37 16.50
 135.78 183.41 16.80887698 3.4469 5.7554 3.575
 3.4236 1.6856 3.832 7.0558 673.779 
56 2 7 185 222 272 297 316 344 159.0  23.15
 24.40 20.20 22.58  159 289 165 164 173 180 160 
 279 0.279 145 225 225 179 161 164 169  136
 122 69 75 111 148 149  7.6  5.27 
 53.8 312 168 144 46.154 0.157 7.472  344
118 
 
 13.1861 1.9067 0.554 4.009 1.166 5.027 1.461 12.309
 3.578 0.41 7.18 95.6 85.87 1132.30 32250 32175 21113 6.108
 80.54 1.577 20.796 100.57 34.61 92.57 22.25 182.24
 279.96 14.3217907 4.6778 10.6969 1.9447
 5.8251 5.7826 5.3258 6.074 965.9085 
57 2 7 184 213 261 298 324 342 158.0  23.10
 27.15 24.65 24.97  126 209 155 139 185 162 193 
 270 0.27 163 249 214 166 179 162 163  140
 125 74 77 111 127 138  6.5  4.64 
 53.1 317 168 149 47.003 0.149 6.802  342
 13.0817 1.9279 0.564 3.440 1.006 4.622 1.351 13.274
 3.881 0.4154 7.11 89.06 94.94 1241.93 30368 32303 20085
 9.396 122.92 1.927 25.203 101.34 39.45 70.57 23.99
 198.48 298.81 21.34302659 4.5959 8.9865
 2.4283 8.1406 1.3845 1.2232 4.4729
 550.524 
58 2 7 200 236 278 308 329 347 147.0  25.60
 . 26.35 25.98  128 238 179 171 157 137 164 
 298 0.298 112 218 186 163 141 140 158  148
 154 121 104 125 142 159  19  5.58 
 54.1 321 173 147 45.794 0.159 7.569  347
 17.964 2.2392 0.645 4.017 1.158 5.262 1.516 13.039
 3.758 0.3814 6.62 204.23 144.85 2602.16 29483
 28455 24173 12.183 218.85 1.973 35.441 101.93
 29.74 98.36 30.32 169.13 219.84 15.14444232 4.2017
 10.9418 0.8975 16.2811 1.2411 6.2621
 2.3428 1003.755 
59 2 7 183 219 269 304 323 350 167.0  21.95
 39.60 24.35 28.63  155 231 171 188 194 165 187 
 287 0.287 135 206 215 181 150 135 132  119
 116 63 69 100 132 140  6.25  4.76 
 52 314 164 151 48.089 0.165 7.613  350
 14.749 2.2024 0.629 4.005 1.144 5.484 1.567 11.050
 3.157 0.3886 7.2 143.38 104.12 1535.74 32970
 28905 19260 9.474 139.73 1.712 25.246 101.43 31.19
 42.80 17.07 132.74 184.51 17.84197436 3.941 6.6268
 4.6053 10.9859 8.7639 7.7188 7.5754
 1483.422 
60 2 7 197 237 283 317 340 365 168.0  24.60
 37.55 24.10 28.75  142 203 182 151 153 182 179 
 297 0.297 118 204 192 181 161 124 126  121
 103 79 88 111 120 1258  8.4  4.91 
 53.7 330 177 153 46.364 0.164 8.018  365
 13.9027 2.2346 0.612 3.921 1.074 5.332 1.461 12.894
 3.533 0.4488 7.1 140.81 111.36 1548.15 30885
 27885 19350 12.680 176.29 2.069 28.761 100.96
 30.57 82.10 26.26 268.46 331.07 16.21580256 4.606
 10.059 2.9693 8.6367 0.6136 8.6997 8.656
 1112.9145 
61 1 3 187 224 280 315 326 346 159.1  20.50
 24.30 24.05 22.95  181 245 181 173 180 216 189 
 283 0.28 123 180 175 153 146 142 125  141
 130 87 85 79 97 141  29  4.5 
 61.5 320 197 123 38.438 0.163 10.433  346
 17.0218 2.1772 0.629 4.110 1.188 5.508 1.592 10.330
 2.986 0.3712 6.49 140.32 125.27 2132.40 35085
 26670 18480 10.143 172.65 2.119 36.072 101.89
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 29.15 531.71 252.13 339.07 432.75 13.92003061
 4.0369 16.7054 1.8194 1.8385 2.3184
 2.3709 2.1556 393.696 
62 1 3 175 209 264 287 309 333 157.7  22.60
 24.30 21.35 22.75  136 180 169 166 232 208 196 
 263 0.26 126 160 165 143 131 133 113  118
 114 81 85 114 124 128  7.5  4.5 
 60.9 295 179 115 38.983 0.159 9.562  333
 12.0112 1.8762 0.563 3.704 1.112 5.185 1.557 11.326
 3.401 0.4459 7.14 91.46 96.85 1163.34 34703 24653 19808
 4.541 54.55 1.889 22.693 101.17 39.18 375.93
 142.69 258.46 35.14 19.04725464 3.301 10.1945
 0.7126 2.7943 0.5 1.0367 1.47 223.32 
63 1 3 181 220 266 300 323 339 157.9  25.50
 25.45 22.45 24.47  142 154 153 166 191 195 147 
 271 0.27 133 203 224 191 168 130 137  125
 110 71 86 87 115 126  9.2  4.2 
 63.8 314 201 114 36.306 0.148 8.979  339
 11.0424 1.7954 0.530 3.938 1.162 5.597 1.651 12.716
 3.751 0.2929 6.76 95.12 74.14 818.67 30713 29813 18330
 4.119 45.49 1.833 20.243 100.69 54.88 81.79 25.09
 247.69 443.94 16.77061412 3.7563 9.4278 4.563
 4.9714 2.2111 1.5371 1.0425 440.5875 
64 1 3 194 232 285 317 343 373 178.8  23.70
 25.55 24.60 24.62  119 129 129 119 130 142 172 
 293 0.29 142 168 200 154 153 156 142  118
 112 63 69 89 113 119  12.5  5.27 
 51.1 337 172 165 48.961 0.162 7.610  373
 17.0418 2.3746 0.637 4.479 1.201 5.571 1.494 11.937
 3.200 0.4407 6.69 90.74 93.23 1588.79 24750 28575 17378
 7.889 134.45 1.579 26.902 101.10 37.74 290.71
 159.40 237.80 522.99 15.71838531 3.859 10.3967
 5.482 4.8746 3.4302 9.8686 4.5216 1110.591 
65 1 3 164 192 237 263 293 315 151.5  22.35
 25.70 22.35 23.47  136 152 140 119 130 142 172 
 238 0.23 107 179 185 137 135 112 115  120
 68 67 66 128 100 99  6.4  5.01 
 48 283 136 147 51.943 0.157 6.488  315
 11.2358 1.9365 0.615 3.249 1.031 4.665 1.481 9.360 2.971
 0.4405 6.7 65.94 71.35 801.65 25470 24300 16718 4.152
 46.65 1.593 17.903 100.13 40.16 60.87 105.49
 257.76 345.56 18.76028315 3.7534 8.0267
 0.6757 3.4893 1.2089 1.6502 . 218.721 
66 2 1 160 180 206 221 236 242 82.0  15.00
 12.65 17.40 15.02  100 203 151 140 160 147 138 
 206 0.206 100 150 109 105 99 101 97  81
 55 32 31 38 45 88  3.5  3.27 
 20.7 228 47 181 79.386 0.145 6.165  242 6.582
 1.6187 0.669 0.950 0.393 1.139 0.471 1.394 0.576 0.3653
 7.2 86.83 78.07 513.86 26948 19028 8888 6.599 43.44 2.103
 13.840 101.00 27.00 40.91 23.81 149.60 101.08
 13.38435049 4.134 3.1907 0.5945 0.653 0.5907
 0.7067 0.6266 116.289 
67 2 1 151 178 215 240 256 265 114.0  17.60
 14.60 19.40 17.20  96 153 176 143 175 144 138 
 219 0.219 110 156 133 117 100 109 105  115
 61 44 32 25 37 78  3  2.98 
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 18.5 256 47 209 81.641 0.156 6.414  265
 8.8707 1.9356 0.730 1.170 0.442 1.288 0.486 2.185 0.824
 0.3828 6.57 107.48 96.19 853.25 27135 20723 8483
 7.658 67.93 1.885 16.725 100.40 23.43 45.73 24.07
 182.08 193.20 13.99655634 2.9266 5.1642 0.556
 1.3848 0.7253 1.0817 0.6846 167.9625 
68 2 1 158 187 211 226 238 247 89.0  18.05
 16.05 17.60 17.23  112 129 154 153 141 146 145 
 212 0.212 96 121 111 99 99 100 105  103
 50 25 33 38 66 82  3  3.2 
 19.6 230 45 185 80.435 0.146 6.091  247
 7.0619 1.7721 0.717 1.060 0.429 1.132 0.458 1.671 0.677
 0.4005 6.92 86.18 69.54 491.08 25980 18623 9645 7.184
 50.73 2.002 14.137 101.04 23.28 41.05 31.55 111.34
 103.97 11.85383585 3.4164 4.9709 0.4863
 0.6528 . 0.6543 1.1868 72.3195 
69 2 1 152 182 208 216 232 240 88.0  18.60
 13.80 17.65 16.68  115 151 160 131 188 146 136 
 201 0.201 89 110 124 105 103 106 94  83
 35 24 36 40 39 83  2.9  2.72 
 19 226 43 183 80.973 0.149 6.048  240
 6.6562 1.6228 0.676 1.051 0.438 1.233 0.514 1.782 0.742
 0.3904 6.77 68.13 65.08 433.17 26948 18938 8213 8.180
 54.45 2.074 13.808 101.46 23.43 46.43 24.24 102.49
 149.72 14.03481921 2.9921 5.3026 0.5245
 0.7603 0.5253 0.6595 1.0332 124.881 
70 2 1 166 193 215 228 236 244 78.0  18.60
 13.65 18.10 16.78  122 153 147 145 148 142 142 
 213 0.213 95 129 122 104 83 103 101  102
 33 34 36 30 32 83  3  2.8 
 20.4 230 47 183 79.565 0.153 6.364  244
 6.9172 1.7411 0.714 0.971 0.398 1.113 0.456 1.833 0.751
 0.4021 6.63 52.42 55.98 387.23 25958 18668 7935 5.787
 40.03 2.007 13.886 100.89 23.43 35.01 19.62 127.84
 114.42 12.54256744 3.0464 4.1008 0.5012
 0.9109 0.7475 0.8305 0.7 . 
 
; 
 
proc sort data = all_groups; by Diet_Group; 
 
proc format;  
 value dietfmt 
  1='Lean Control' 
  2='Obese Control' 
  3='High Germ' 
  4='Whole Wheat' 
  5='Refined Wheat' 
  6='Bran' 
  7='Germ'; 
  
proc print data= all_groups; by Diet_Group; format Diet_Group dietfmt.; 
 
proc means data=all_groups n mean stderr min max; by Diet_Group; format 
Diet_Group dietfmt.; 
var Tot_FA_absorpPC Free_FA_absorpPC Daily_Tot_FA_intake 
Daily_free_FA_intake FA; 
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run; 
 
proc glm data= all_groups; 
title 'One Way Analysis of Variance in all rats'; 
format Diet_Group dietfmt.; 
class Diet_Group Block_No; 
model Initial_BW--AUC_MMT_Insulin Daily_Tot_FA_intake--
Free_FA_absorpPC=Diet_Group Block_No; 
Means Diet_Group / Duncan; 
LSMeans Diet_Group / STDERR pdiff; 
run; 
proc glm data= zdf_only; 
title 'One Way Analysis of Variance in ZDF rats'; 
format Diet_Group dietfmt.; 
class Diet_Group Block_No; 
model Initial_BW--AUC_MMT_Insulin Daily_Tot_FA_intake--
Free_FA_absorpPC=Diet_Group Block_No; 
Means Diet_Group / Duncan; 
LSMeans Diet_Group / STDERR pdiff; 
run; 
proc corr data=all_groups; 
title 'Correlation of Fecal Bile Acids and Liver Cholesterol in all 
rats'; 
format Diet_Group dietfmt.; 
var Liver_total_chol_conc_true resistin_sample_ngml; 
with fecal_bile_acid Body_Fat_DXA; 
run; 
proc corr data=zdf_only; 
title 'Correlation of Fecal Bile Acids and Liver Cholesterol in zdf 
rats'; 
format Diet_Group dietfmt.; 
var Liver_total_chol_conc_true resistin_sample_ngml; 
with fecal_bile_acid Body_Fat_DXA; 
run; 
quit; 
 
